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A B S T R A C T
Background
Hepatorenal syndrome is defined as renal failure in people with cirrhosis in the absence of other causes. In addition to supportive treat-
ment such as albumin to restore fluid balance, the other potential treatments include systemic vasoconstrictor drugs (such as vasopressin
analogues or noradrenaline), renal vasodilator drugs (such as dopamine), transjugular intrahepatic portosystemic shunt (TIPS), and liv-
er support with molecular adsorbent recirculating system (MARS). There is uncertainty over the best treatment regimen for hepatorenal
syndrome.
Objectives
To compare the benefits and harms of different treatments for hepatorenal syndrome in people with decompensated liver cirrhosis.
Search methods
We searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials Reg-
istry Platform, and trial registers until December 2018 to identify randomised clinical trials on hepatorenal syndrome in people with cir-
rhosis.
Selection criteria
We included only randomised clinical trials (irrespective of language, blinding, or publication status) in adults with cirrhosis and hepa-
torenal syndrome. We excluded randomised clinical trials in which participants had previously undergone liver transplantation.
Data collection and analysis
Two authors independently identified eligible trials and collected data. The outcomes for this review included mortality, serious adverse
events, any adverse events, resolution of hepatorenal syndrome, liver transplantation, and other decompensation events. We performed
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a network meta-analysis with OpenBUGS using Bayesian methods and calculated the odds ratio (OR), rate ratio, hazard ratio (HR), and
mean difference (MD) with 95% credible intervals (CrI) based on an available-case analysis, according to National Institute of Health and
Care Excellence Decision Support Unit guidance.
Main results
We included a total of 25 trials (1263 participants; 12 interventions) in the review. Twenty-three trials (1185 participants) were included
in one or more outcomes. All the trials were at high risk of bias, and all the evidence was of low or very low certainty. The trials included
participants with liver cirrhosis of varied aetiologies as well as a mixture of type I hepatorenal syndrome only, type II hepatorenal syndrome
only, or people with both type I and type II hepatorenal syndrome. Participant age ranged from 42 to 60 years, and the proportion of
females ranged from 5.8% to 61.5% in the trials that reported this information. The follow-up in the trials ranged from one week to six
months. Overall, 59% of participants died during this period and about 35% of participants recovered from hepatorenal syndrome. The
most common interventions compared were albumin plus terlipressin, albumin plus noradrenaline, and albumin alone.
There was no evidence of a difference in mortality (22 trials; 1153 participants) at maximal follow-up between the different interventions.
None of the trials reported health-related quality of life. There was no evidence of differences in the proportion of people with serious
adverse events (three trials; 428 participants), number of participants with serious adverse events per participant (two trials; 166 partic-
ipants), proportion of participants with any adverse events (four trials; 402 participants), the proportion of people who underwent liver
transplantation at maximal follow-up (four trials; 342 participants), or other features of decompensation at maximal follow-up (one trial;
466 participants). Five trials (293 participants) reported number of any adverse events, and five trials (219 participants) reported treatment
costs. Albumin plus noradrenaline had fewer numbers of adverse events per participant (rate ratio 0.51, 95% CrI 0.28 to 0.87). Eighteen trials
(1047 participants) reported recovery from hepatorenal syndrome (as per definition of hepatorenal syndrome). In terms of recovery from
hepatorenal syndrome, in the direct comparisons, albumin plus midodrine plus octreotide and albumin plus octreotide had lower recov-
ery from hepatorenal syndrome than albumin plus terlipressin (HR 0.04; 95% CrI 0.00 to 0.25 and HR 0.26, 95% CrI 0.07 to 0.80 respectively).
There was no evidence of differences between the groups in any of the other direct comparisons. In the network meta-analysis, albumin
and albumin plus midodrine plus octreotide had lower recovery from hepatorenal syndrome compared with albumin plus terlipressin.
Funding: two trials were funded by pharmaceutical companies; five trials were funded by parties who had no vested interest in the results
of the trial; and 18 trials did not report the source of funding.
Authors' conclusions
Based on very low-certainty evidence, there is no evidence of benefit or harm of any of the interventions for hepatorenal syndrome with
regards to the following outcomes: all-cause mortality, serious adverse events (proportion), number of serious adverse events per partici-
pant, any adverse events (proportion), liver transplantation, or other decompensation events. Low-certainty evidence suggests that albu-
min plus noradrenaline had fewer 'any adverse events per participant' than albumin plus terlipressin. Low- or very low-certainty evidence
also found that albumin plus midodrine plus octreotide and albumin alone had lower recovery from hepatorenal syndrome compared
with albumin plus terlipressin.
Future randomised clinical trials should be adequately powered; employ blinding, avoid post-randomisation dropouts or planned cross-
overs (or perform an intention-to-treat analysis); and report clinically important outcomes such as mortality, health-related quality of life,
adverse events, and recovery from hepatorenal syndrome. Albumin plus noradrenaline and albumin plus terlipressin appear to be the
interventions that should be compared in future trials.
P L A I N   L A N G U A G E   S U M M A R Y
Treatment of hepatorenal syndrome
What is the aim of this Cochrane review?
To find out the best treatment for decreased kidney function (hepatorenal syndrome) in people with liver cirrhosis (a form of advanced liver
disease with scarring of the liver) with complications. The authors collected and analysed all relevant studies to answer this question and
found 25 randomised controlled trials (participants receive the treatment based on method similar to coin toss or lottery; this is to ensure
that the people who receive the different treatments are similar in all aspects except the treatment, so that any differences in the results
between the treatments can be attributed to the treatment rather than differences in the type of people who received the treatment).
During analysis of data, authors used standard Cochrane techniques, which allows comparison of two treatments at a time. Authors also
used advanced techniques, that allow comparison of many treatments at the same time (usually referred as 'network meta-analysis' or
'multiple treatment comparisons'). The aim is to gather reliable evidence on the relative benefits and harms of the different treatments.
Date of literature search
December 2018
Key messages
Only one of the studies was conducted well. The remaining studies had one or more flaws. Therefore, there is high uncertainty in the
results of the analysis. The authors could not recommend one treatment over another on the basis of risk of death, serious complications,
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percentage of people who developed any complication, percentage of participants who underwent liver transplantation (replacement of
a diseased liver with a healthy one), or the number of other liver failure events. Health-related quality of life was not reported in any of the
trials. The number of complications of any severity was lower with albumin plus noradrenaline than albumin plus terlipressin. Recovery
from hepatorenal syndrome may be lower with albumin plus midodrine plus octreotide and albumin alone than albumin plus terlipressin
and albumin plus noradrenaline.
Funding source was unclear in 18 studies. Industrial organisations funded two studies and the remaining five studies did not receive any
funding from industrial organisations.
What was studied in the review?
This review studied people of any sex, age, and origin, having advanced liver disease due to various causes, and who had developed hepa-
torenal syndrome. People were administered different treatments. The review authors excluded studies with liver-transplanted partici-
pants. Participants age, when reported, ranged from 42 to 60 years. The number of females ranged from 6 to 62 out of 100 in the studies that
reported this information. The main treatments compared were albumin alone, albumin plus terlipressin, and albumin plus noradrena-
line. The authors gathered and analysed data on death, quality of life, serious and non-serious complications, time to liver transplantation,
recovery from hepatorenal syndrome, and disappearance of symptoms.
What were the main results of the review?
The 25 studies included a small number of participants (1263 participants). Study data were sparse. Twenty-three studies with 1185 par-
ticipants provided data for analyses. The follow-up in the trials ranged from one week to six months. The review shows that:
- About 60 out of every 100 people died within three months, and 35 out of every 100 people recovered from hepatorenal syndrome.
- The provided treatment may make no difference to the percentage of people who died or developed serious complications, number
of serious complications per person, percentage of people who developed complications of any severity, or the percentage of people
undergoing liver transplantation.
- None of the trials reported health-related quality of life.
- The number of complications of any severity was lower with albumin plus noradrenaline than albumin plus terlipressin.
- Recovery from hepatorenal syndrome may be lower with albumin plus midodrine plus octreotide and albumin alone than albumin plus
terlipressin and albumin plus noradrenaline.
- We have very low confidence in the overall results.
- Future trials with proper design and quality are needed to clarify the best treatment for people with advanced liver disease having he-
patorenal syndrome.
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Summary of findings for the main comparison.
Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis
Patient or population: people with hepatorenal syndrome with decompensated liver cirrhosis
Intervention: various interventions
Comparison: albumin plus terlipressin
Setting: tertiary care
Follow-up period: 1 week to 6 months
Network geometry plots: Figure 1
Anticipated absolute effect** (95% CrI)Interventions Relative effect
(95% CrI)* Albumin plus
terlipressin
Various interven-
tions
Difference
Certainty of
evidence
Ranking***
Mortality at maximal follow-up
Total studies: 19
Total participants: 1089
Albumin plus no-
radrenaline
(9 RCTs; 486 partic-
ipants)
HR 1.33
(0.87 to 2.00)
Network estimate
517 per 1000 687 per 1000
(449 to 1000)
170 more per 1000
(68 fewer to 483 more)
Very low1,2,3 -
Albumin
(6 RCTs; 480 partic-
ipants)
HR 1.06
(0.69 to 1.80)
Network estimate
517 per 1000 549 per 1000
(354 to 932)
32 more per 1000
(163 fewer to 415 more)
Very low1,2,3 -
Albumin plus mi-
dodrine plus oc-
treotide
(1 RCT; 48 partici-
pants)
HR 1.42
(0.52 to 3.79)
Network estimate
517 per 1000 734 per 1000
(267 to 1000)
217 more per 1000
(250 fewer to 483 more)
Very low1,2,3 -
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Albumin plus mi-
dodrine plus oc-
treotide plus pen-
toxifylline
(No RCTs)
HR 0.50
(0.06 to 4.07)
Network estimate
517 per 1000 259 per 1000
(29 to 1000)
258 fewer per 1000
(488 fewer to 483 more)
Very low1,2,3 -
Albumin plus oc-
treotide
(1 RCT; 40 partici-
pants)
HR 1.46
(0.35 to 6.49)
Network estimate
517 per 1000 752 per 1000
(180 to 1000)
235 more per 1000
(337 fewer to 483 more)
Very low1,2,3 -
Health-related quality of life
None of the trials reported this outcome
Serious adverse events (proportion)
Total studies: 3
Total participants: 428
Albumin plus no-
radrenaline
(1 RCT; 120 partici-
pants)
OR 0.82
(0.21 to 2.98)
Network estimate
608 per 1000 560 per 1000
(250 to 822)
48 fewer per 1000
(358 fewer to 214 more)
Very
low1,2,4,5
-
Albumin
(2 RCTs; 308 partic-
ipants)
OR 0.80
(0.50 to 1.26)
Network estimate
608 per 1000 553 per 1000
(438 to 662)
55 fewer per 1000
(170 fewer to 54 more)
Very
low1,2,4,5
 
Serious adverse events (number per participant)
Total studies: 2
Total participants: 166
Albumin plus no-
radrenaline
(1 RCT; 120 partici-
pants)
Rate ratio 0.83
(0.23 to 2.83)
Network estimate
100 per 1000 83 per 1000
(23 to 283)
17 fewer per 1000
(77 fewer to 183 more)
Very
low1,2,4,5
-
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Albumin
(1 RCT; 46 partici-
pants)
Rate ratio 0.91
(0.51 to 1.65)
Network estimate
100 per 1000 91 per 1000
(51 to 165)
9 fewer per 1000
(49 fewer to 65 more)
Very
low1,2,4,5
-
Any adverse events (proportion)
Total studies: 4
Total participants: 402
Albumin plus no-
radrenaline
(1 RCT; 46 partici-
pants)
OR 0.16
(0.01 to 1.44)
Network estimate
928 per 1000 674 per 1000
(114 to 949)
254 fewer per 1000
(814 fewer to 21 more)
Very
low1,2,4,5
1
(1 to 4)
Albumin
(2 RCTs; 308 partic-
ipants)
OR 0.58
(0.25 to 1.25)
Network estimate
928 per 1000 882 per 1000
(765 to 941)
46 fewer per 1000
(163 fewer to 13 more)
Very
low1,2,4,5
2
(1 to 4)
Albumin plus terli-
pressin
Reference treatment 3
(2 to 4)
Albumin plus mi-
dodrine plus oc-
treotide
(1 RCT; 48 partici-
pants)
OR 1.14
(0.30 to 4.30)
Network estimate
928 per 1000 936 per 1000
(795 to 982)
8 more per 1000
(133 fewer to 54 more)
Very
low1,2,4,5
4
(1 to 4)
Any adverse events (number)
Total studies: 5
Total participants: 293
Albumin plus no-
radrenaline
(4 RCTs; 293 partic-
ipants)
Rate ratio 0.51
(0.28 to 0.87)
Direct estimate
317 per 1000 161 per 1000
(88 to 276)
156 fewer per 1000
(229 fewer to 41 fewer)
Low1,4 1
(1 to 2)
Albumin Rate ratio 0.80
(0.52 to 1.22)
317 per 1000 252 per 1000
(166 to 386)
65 fewer per 1000
(151 fewer to 69 more)
Very
low1,2,4,5
2
(1 to 3)
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(1 RCT; 48 partici-
pants)
Network estimate
Albumin plus terli-
pressin
Reference treatment 3
(2 to 3)
Liver transplantation at maximal follow-up
Total studies: 3
Total participants: 330
Albumin plus no-
radrenaline
(1 RCT; 48 partici-
pants)
HR 1.09
(0.36 to 3.31)
Network estimate
309 per 1000 336 per 1000
(110 to 1000)
27 more per 1000
(199 fewer to 691 more)
Very
low1,2,4,5
-
Albumin
(2 RCTs; 308 partic-
ipants)
HR 1.01
(0.68 to 1.52)
Network estimate
309 per 1000 313 per 1000
(210 to 469)
4 more per 1000
(99 fewer to 160 more)
Very
low1,2,4,5
-
Recovery from hepatorenal syndrome at maximal follow-up
Total studies: 18
Total participants: 1047
Albumin plus no-
radrenaline
(10 RCTs; 518 par-
ticipants)
HR 0.85
(0.58 to 1.28)
Network estimate
400 per 1000 340 per 1000
(230 to 512)
60 fewer per 1000
(170 fewer to 112 more)
Very
low1,2,3,4,5
-
Albumin
(4 RCTs; 406 partic-
ipants)
HR 0.28
(0.14 to 0.53)
Network estimate
400 per 1000 111 per 1000
(54 to 213)
289 fewer per 1000
(346 fewer to 187 fewer)
Very
low1,3,4,5
-
Albumin plus mi-
dodrine plus oc-
treotide
(1 RCT; 48 partici-
pants)
HR 0.04
(0.00 to 0.25)
Direct estimate
400 per 1000 17 per 1000
(1 to 101)
383 fewer per 1000
(399 fewer to 299 fewer)
Very
low1,3,4,5,6
-
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Albumin plus mi-
dodrine plus oc-
treotide plus pen-
toxifylline
(No RCTs)
HR 0.25
(0.00 to 12.85)
Network estimate
400 per 1000 99 per 1000
(2 to 1000)
301 fewer per 1000
(398 fewer to 600 more)
Very
low1,2,3,4,5
-
Albumin plus oc-
treotide
(1 RCT; 40 partici-
pants)
HR 0.26
(0.07 to 0.80)
Direct estimate
400 per 1000 105 per 1000
(28 to 321)
295 fewer per 1000
(372 fewer to 79 more)
Low1,4 -
Other episodes of decompensation (per participant)
Total studies: 1
Total participants: 46
Albumin plus terli-
pressin
Reference treatment 1
(1 to 2)
Albumin
(1 RCT; 46 partici-
pants)
Rate ratio 1.10
(0.60 to 2.03)
Direct estimate
870 per 1000 959 per 1000
(518 to 1000)
89 more per 1000
(352 fewer to 130 more)
Very low1,2,4 2
(1 to 2)
*Direct estimates have been provided when there the quality of evidence is better for direct estimates than network estimates or when only the direct estimates were avail-
able.
**Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risks of the intervention group with the weighted
median risk of the control group.
***Ranking is provided only when the median rank was 1 for at least one of the ranking positions for each intervention for the outcome. When ranking is available, the treat-
ments are ordered according to the ranks; otherwise, they are arranged according to the number of trials featuring the intervention.
CrI: credible intervals; HR: hazard ratio; OR: odds ratio.
GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low certainty: We are very uncertain about the estimate.
1Risk of bias: trial(s) were at high risk of bias (downgraded by one level).
2Imprecision: credible intervals overlapped a clinically significant benefits and harms (downgraded by one level).
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3Heterogeneity: there were differences in the effect estimates obtained by fixed-effect model and random-effects models (downgraded by one level).
4Imprecision: small sample size (downgraded by one level)
5Indirectness: sparse network made up of trials at high risk of bias (downgraded by one level)
6Indirectness: incongruence (the inconsistency factor plot demonstrated inconsistency in the loop (downgraded by one level).
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Figure 1.   The network plots showing the outcomes for which network meta-analysis was performed. The size of the node (circle) provides a measure
of the number of trials in which the particular Intervention was included as one of the intervention groups. The thickness of the line provides a
measure of the number of direct comparisons between two nodes (Interventions). Abbreviations: Pent = Pentoxyfylline The individual figures are
available in the online supplement.
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Summary of findings 2.
Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis (the two interventions with maximum number of trials)
Patient or population: people with hepatorenal syndrome with decompensated liver cirrhosis
Intervention: various interventions
Comparison: albumin and terlipressin
Setting: tertiary care
Follow-up period: 1 week to 6 months
Network geometry plots: Figure 1
Outcomes Albumin Albumin plus noradrenaline
Mortality at maximal follow-up
HR 1.06
(0.69 to 1.80)
Network estimate
32 more per 1000
(163 fewer to 415 more)
HR 1.33
(0.87 to 2.00)
Network estimate
170 more per 1000
(68 fewer to 483 more)
Albumin plus terlipressin
comparator
517 per 1000
(51.7%)
Very low1,2,3
confidence in estimate
Very low1,2,3
confidence in estimate
Rank: - Rank: -Rank*: -
Based on 480 participants (6 RCTs) Based on 486 participants (9 RCTs)
Health-related quality of life
None of the trials reported this outcome
Serious adverse events (proportion of participants)
Albumin plus terlipressin
comparator
608 per 1000
(60.8%)
OR 0.80
(0.50 to 1.26)
Network estimate
55 fewer per 1000
(170 fewer to 54 more)
OR 0.82
(0.21 to 2.98)
Network estimate
48 fewer per 1000
(358 fewer to 214 more)
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Very low1,2,4,5
confidence in estimate
Very low1,2,4,5
confidence in estimate
Rank: - Rank: -Rank: -
Based on 308 participants (2 RCTs) Based on 120 participants (1 RCT)
Serious adverse events (number per participant)
Rate ratio 0.91
(0.51 to 1.65)
Network Estimate
9 fewer per 1000
(49 fewer to 65 more)
Rate ratio 0.83
(0.23 to 2.83)
Network estimate
17 fewer per 1000
(77 fewer to 183 more)
Albumin plus terlipressin
comparator
100 per 1000
(10.0 per 100 participants)
Very low1,2,4,5
confidence in estimate
Very low1,2,4,5
confidence in estimate
Rank: - Rank: -Rank: -
Based on 46 participants (1 RCT) Based on 120 participants (1 RCT)
Any adverse events (proportion of participants)
OR 0.58
(0.25 to 1.25)
Network estimate
46 fewer per 1000
(163 fewer to 13 more)
OR 0.16
(0.01 to 1.44)
Network Estimate
254 fewer per 1000
(814 fewer to 21 more)
Albumin plus terlipressin
comparator
928 per 1000
(92.8%)
Very low1,2,4,5
confidence in estimate
Very low1,2,4,5
confidence in estimate
Rank: 3
(2 to 4)
Rank: 2
(1 to 4)
Rank: 1
(1 to 4)
  Based on 308 participants (2 RCTs) Based on 46 participants (1 RCT)
Any adverse events (number per participant)
Albumin plus terlipressin
comparator
317 per 1000
Rate ratio 0.80
(0.52 to 1.22)
65 fewer per 1000
(151 fewer to 69 more)
Rate ratio 0.51
(0.28 to 0.87)
156 fewer per 1000
(229 fewer to 41 fewer)
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Network estimate Direct estimate**(31.7 per 100 participants)
Very low1,2,4,5
confidence in estimate
Low1,2
confidence in estimate
Rank: 2
(1 to 3)
Rank: 1
(1 to 2)
Rank: 3
(2 to 3)
Based on 48 participants (1 RCT) Based on 293 participants (4 RCTs)
Liver transplantation at maximal follow-up
HR 1.01
(0.68 to 1.52)
Network estimate
4 more per 1000
(99 fewer to 160 more)
HR 1.09
(0.36 to 3.31)
Network estimate
27 more per 1000
(199 fewer to 691 more)
Albumin plus terlipressin
comparator
309 per 1000
(30.9%)
Very low1,2,4,5
confidence in estimate
Very low1,2,4,5
confidence in estimate
Rank: - Rank: - Rank: -
  Based on 308 participants (2 RCTs) Based on 48 participants (1 RCT)
Recovery from hepatorenal syndrome at maximal follow-up
HR 0.28
(0.14 to 0.53)
Network estimate
289 fewer per 1000
(346 fewer to 187 fewer)
HR 0.85
(0.58 to 1.28)
Network estimate
60 fewer per 1000
(170 fewer to 112 more)
Albumin plus terlipressin
comparator
400 per 1000
(40.0%)
Very low1,3,4,5
confidence in estimate
Very low1,2,3,4,5
confidence in estimate
Rank: - Rank: -Rank: -
Based on 406 participants (4 RCTs) Based on 518 participants (10 RCTs)
Other episodes of decompensation (per participant)
Albumin plus terlipressin
comparator
870 per 1000
Rate ratio 1.10
(0.60 to 2.03)
89 more per 1000
(352 fewer to 130 more)
Not reported
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Direct estimate**(87.0%)
Very low1,2,4
confidence in estimate
Rank: 2
(1 to 2)
Rank: 1
(1 to 2)
Based on 46 participants (1 RCT)
*Ranking is provided only when the median rank was 1 for at least one of the ranking positions for each intervention for the outcome. When ranking is available, the treat-
ments are ordered according to the ranks; otherwise, they are arranged according to the number of trials featuring the intervention.
**Direct estimates have been provided when there the quality of evidence is better for direct estimates than network estimates or when only the direct estimates were
available.
CrI: credible intervals; HR: hazard ratio; OR: odds ratio.
GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low certainty: We are very uncertain about the estimate.
1Risk of bias: trial(s) were at high risk of bias (downgraded by one level).
2Imprecision: credible intervals overlapped a clinically significant benefits and harms (downgraded by one level).
3Heterogeneity: there were differences in the effect estimates obtained by fixed-effect model and random-effects model (downgraded by one level).
4Imprecision: small sample size (downgraded by one level)
5Indirectness: sparse network made up of trials at high risk of bias (downgraded by one level)
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B A C K G R O U N D
Description of the condition
Liver cirrhosis
The liver is a complex organ with multiple functions including
carbohydrate metabolism, fat metabolism, protein metabolism,
drug metabolism, synthetic functions, storage functions, digestive
functions, excretory functions, and immunological functions (Read
1972). Liver cirrhosis is a liver disease in which the normal micro-
circulation, the gross vascular anatomy, and the hepatic architec-
ture have been variably destroyed and altered with fibrous sep-
ta surrounding regenerated or regenerating parenchymal nodules
(Tsochatzis 2014; NCBI 2018). The major causes of liver cirrhosis
include excessive alcohol consumption, viral hepatitis, non-alco-
hol-related fatty liver disease, autoimmune liver disease, and meta-
bolic liver disease (Williams 2014; Ratib 2015; Setiawan 2016). The
global prevalence of liver cirrhosis is difficult to estimate as most
estimates correspond to chronic liver disease (which includes liver
fibrosis and liver cirrhosis). In studies from the USA, the prevalence
of chronic liver disease varies between 0.3% to 2.1% (Scaglione
2015; Setiawan 2016); in the UK, the prevalence was 0.1% in one
study (Fleming 2008). In 2010, liver cirrhosis was responsible for an
estimated 2% of all global deaths, equivalent to one million deaths
(Mokdad 2014). There is an increasing trend of cirrhosis-related
deaths in some countries like the UK, while there is a decreasing
trend in other countries like France (Mokdad 2014; Williams 2014).
The major cause of complications and deaths in people with liver
cirrhosis is due to the development of clinically significant portal
hypertension (hepatic venous pressure gradient at least 10 mmHg)
(De Franchis 2015). Some of the clinical features of decompensa-
tion include jaundice, coagulopathy, ascites, variceal bleeding, he-
patic encephalopathy, and renal failure (De Franchis 2015; McPher-
son 2016; EASL 2018). Decompensated cirrhosis is the most com-
mon indication for liver transplantation (Merion 2010; Adam 2012).
Hepatorenal syndrome
Hepatorenal syndrome is renal failure in people with cirrhosis in the
absence of other causes of renal failure such as nephrotoxic drugs
and underlying renal pathology (Angeli 2015a). It is considered a
functional disorder not associated with structural kidney damage
and is potentially reversible. The current criteria for the diagnosis of
hepatorenal syndrome are provided in Table 1 (Angeli 2015a). He-
patorenal syndrome can be classified into type I and type II hepa-
torenal syndrome. Type I hepatorenal syndrome has a rapidly pro-
gressive reduction in renal function, while type II hepatorenal syn-
drome does not follow a rapidly progressive course (Arroyo 1996).
Type I hepatorenal syndrome is associated with acute kidney in-
jury, while type II hepatorenal syndrome is associated with chronic
kidney disease (Wong 2011). However, the most recent diagnostic
criteria of hepatorenal syndrome include acute kidney injury (An-
geli 2015a), that is, most individuals classified as having hepatore-
nal syndrome per the current definition will fall under the type I
hepatorenal syndrome of past definitions. Approximately 10% of
patients hospitalised for other complications of cirrhosis develop
hepatorenal syndrome (Dong 2016). Approximately 30% to 60% of
people hospitalised for hepatorenal syndrome die within a year (Is-
raelsen 2017). The annual direct medical costs of treatment of he-
patorenal syndrome range between approximately USD 3 billion
(3000 million) and USD 3.8 billion (3800 million) (Rice 2017).
Pathophysiology of hepatorenal syndrome
Portal hypertension causes arterial vasodilatation of the splanch-
nic circulation (dilation of the blood vessels supplying the diges-
tive organs in the abdomen such as liver, pancreas, and intestines)
(Gines 2009). This decreases the intravascular volume. In the ear-
ly stages of portal hypertension, the body maintains arterial blood
pressure by increasing the cardiac output; however, in later stages
of portal hypertension, the increase in cardiac output is not suf-
ficient to ensure sufficient blood supply to vital organs, and the
body maintains arterial blood pressure by the activation of vaso-
constrictor mechanisms (Gines 2009). These vasoconstrictor mech-
anisms include the renin–angiotensin system, the sympathetic ner-
vous system, and non-osmotic hypersecretion of antidiuretic hor-
mone (Gines 2009), and lead to decreased blood flow to the kidneys
by renal arterial vasoconstriction, and eventually to renal failure
(Gines 2009).
Description of the intervention
Development of hepatorenal syndrome is considered one of the
manifestations of end-stage liver disease, which is one of the indi-
cations for liver transplantation (EASL 2016). Liver transplantation
is considered the definitive treatment for hepatorenal syndrome in
people who can undergo liver transplantation (Gines 2009; Aceve-
do 2017; EASL 2018). Supportive measures like treatment of the
precipitating cause of renal failure, such as infections or gastroin-
testinal bleeding and fluid overload, should be provided to peo-
ple during waiting time for liver transplantation and to people who
cannot undergo liver transplantation due to contraindications (e.g.
metastatic liver disease) (Gines 2009; EASL 2016). In addition, treat-
ment of hepatorenal syndrome in the form of systemic vasocon-
strictor drugs such as vasopressin analogues or noradrenaline, as
well as renal vasodilator drugs such as dopamine, albumin, tran-
sjugular intrahepatic portosystemic shunt (TIPS), liver support with
molecular adsorbent recirculating system (MARS), and renal re-
placement therapy in the form of haemodialysis or haemofiltration
have been used while waiting for liver transplantation or in people
in whom transplantation cannot be performed (Gines 2009; Hino-
josa-Azaola 2014; Acevedo 2017; Allegretti 2017; EASL 2018).
How the intervention might work
Systemic vasoconstrictor drugs decrease the systemic vasodila-
tion, which is one of the mechanisms of developing hepatorenal
syndrome. Renal vasodilator drugs decrease the renal vasocon-
striction, which is one of the mechanisms of developing hepatore-
nal syndrome. Decreased intravascular volume is one of the mecha-
nisms of developing hepatorenal syndrome; albumin may increase
the intravascular oncotic pressure and prevent third-space loss, re-
sulting in maintenance of the intravascular volume (Caironi 2009).
Transjugular intrahepatic portosystemic shunt results in a reduc-
tion of portal hypertension, which is one of the mechanisms of de-
veloping hepatorenal syndrome. Liver support with MARS and re-
nal replacement therapy can be considered as bridging measures
to prevent further deterioration of patients until the time of liver
transplantation, or recovery from the precipitating factors (e.g. in-
fections or gastrointestinal bleeding).
Why it is important to do this review
It is important to provide optimal treatment to people with hepa-
torenal syndrome to improve their clinical outcomes while wait-
ing for liver transplantation or potentially prevent the need for
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transplantation, or both. This is particularly important, given the
shortage of donor organs. Several different treatments are avail-
able; however, their relative efficacy and optimal combination are
not known. There have been two Cochrane Reviews on hepatore-
nal syndrome treatment (Allegretti 2017; Israelsen 2017); howev-
er, there has been no previous network meta-analysis on the topic.
Network meta-analysis allows for a combination of direct and indi-
rect evidence; and the ranking of different interventions for differ-
ent outcomes (Salanti 2011; Salanti 2012). With this systematic re-
view and network meta-analysis, we aim to provide the best level of
evidence for the benefits and harms of different treatments for he-
patorenal syndrome in people with decompensated liver cirrhosis.
If it is not possible to perform this review with network meta-analy-
sis methods, we will instead use standard Cochrane methods to
perform head-to-head comparison meta-analysis, whenever possi-
ble. We will also present results from direct comparisons, whenev-
er possible, even if we perform the network meta-analysis.
A glossary of terms is provided in Appendix 1.
O B J E C T I V E S
To compare the benefits and harms of different treatments for he-
patorenal syndrome in people with decompensated liver cirrhosis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered randomised clinical trials for this network meta-
analysis irrespective of language, publication status, or date of
publication. We excluded studies of other designs due to the risk
of bias in such studies. Inclusion of indirect observational evidence
could weaken our network meta-analysis, but this could also be
viewed as a strength for assessing rare adverse events. It is well es-
tablished that exclusion of non-randomised studies increases the
focus on potential benefits and reduces the focus on the risks of
serious adverse events and those of any adverse events. Howev-
er, due to the exponentially increased amount of work required for
non-randomised studies, we planned to register and perform a new
systematic review and meta-analysis of non-randomised studies
for adverse events, if there was uncertainty in the balance of ben-
efits and harms of effective treatment(s). We did not perform this
because of the findings of the review.
Types of participants
We included randomised clinical trials with adult trial participants
undergoing treatment for hepatorenal syndrome with decompen-
sated liver cirrhosis. We excluded randomised clinical trials in
which participants had previously undergone liver transplantation.
Types of interventions
We included any of the following interventions for comparison with
one another; either alone, or in combination.
• Noradrenaline (systemic vasoconstrictor)
• Terlipressin (systemic vasoconstrictor)
• Midodrine (systemic vasoconstrictor)
• Dopamine (renal vasodilator)
• Prostaglandins (renal vasodilator)
• Albumin (maintain intravascular volume)
• TIPS procedure (decrease portal hypertension)
• Other forms of portosystemic shunt (decrease portal hyperten-
sion)
• Haemodialysis (renal replacement therapy)
• Haemofiltration (renal replacement therapy)
• MARS (liver support)
• No active intervention (no intervention or placebo)
We evaluated the plausibility of transitivity assumption by looking
at the inclusion and exclusion criteria in the studies. The transitiv-
ity assumption is the assumption that participants included in the
different trials with different treatments for hepatorenal syndrome
can be considered to be a part of a multi-arm randomised clini-
cal trial and could potentially have been randomised to any of the
interventions (Salanti 2012). In other words, any participant that
meets the inclusion criteria is, in principle, equally likely to be ran-
domised to any of the above eligible interventions. This necessi-
tates that information on potential effect-modifiers such as type of
hepatorenal syndrome (type I or type II) and the co-interventions
(use of prophylactic antibiotics) are the same across trials. Since,
there was no concern about the transitivity assumption, we did not
perform a separate meta-analysis on people with cirrhosis and he-
patorenal syndrome with and without other features of decompen-
sation.
Types of outcome measures
Primary outcomes
• All-cause mortality at maximal follow-up (time to death).
• Health-related quality of life using a validated scale such as the
EQ-5D or 36-Item Short Form Health Survey (SF-36) at maximal
follow-up (EuroQol 2018; Optum 2018).
• Serious adverse events (during or within six months after ces-
sation of intervention). We defined a serious adverse event as
any event that would increase mortality; is life-threatening; re-
quires hospitalisation; results in persistent or significant disabil-
ity; is a congenital anomaly/birth defect; or any important med-
ical event that might jeopardise the person or require interven-
tion to prevent it (ICH-GCP 1997). However, none of the authors
defined serious adverse events. Therefore, we used the defini-
tions provided by trial authors for serious adverse events (as in-
dicated in our protocol).
* Proportion of people with one or more serious adverse
events.
* Number of serious adverse events per participant.
Secondary outcomes
• Any adverse events (during or within six months after cessation
of intervention). We defined an adverse event as any untoward
medical occurrence not necessarily having a causal relationship
with the intervention but resulting in a dose reduction or dis-
continuation of intervention (any time after commencement of
intervention) (ICH-GCP 1997). However, none of the authors de-
fined 'adverse event'. Therefore, we used the lists provided by
trial authors for adverse events (as indicated in our protocol).
* Proportion of people with one or more adverse events.
* Number of any adverse events per participant.
• Time to liver transplantation (maximal follow-up).
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• Time to recovery from hepatorenal syndrome (maximal fol-
low-up).
* Symptomatic recovery.
* Recovery as per definitions used for hepatorenal syndrome.
• Time to other features of decompensation (maximal follow-up).
Exploratory outcomes
• Length of hospital stay (all hospital admissions until maximal
follow-up).
• Number of days of lost work (in people who work) (maximal fol-
low-up).
• Treatment costs (including the cost of the treatment and any re-
sulting complications).
We chose outcomes based on their importance to patients in a sur-
vey related to research priorities for people with liver diseases (Gu-
rusamy 2019); on feedback of the patient and public representative
of this project; and on an online survey about the outcomes pro-
moted through Cochrane Consumer Network.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library, MEDLINE Ovid, Embase Ovid,
and Science Citation Index Expanded (Web of Science) from incep-
tion to December 2018 for randomised clinical trials comparing
two or more of the above interventions, applying no language re-
strictions (Royle 2003). We searched for all possible comparisons
formed by the interventions of interest. To identify further ongo-
ing or completed trials, we also searched the US National Insti-
tutes of Health Ongoing Trials Register ClinicalTrials.gov (clinical-
trials.gov) and the World Health Organization International Clinical
Trials Registry Platform (WHO ICTRP) (apps.who.int/trialsearch/),
which searches various trial registers, including ISRCTN and Clin-
icalTrials.gov. We also searched the European Medicines Agency
(EMA) (www.ema.europa.eu/ema/) and US Food and Drug Admin-
istration (FDA) (www.fda.gov) registries for randomised clinical tri-
als. The provisional search strategies are provided in Appendix 2.
Searching other resources
We searched the references of the identified trials and the existing
Cochrane Reviews on hepatorenal syndrome to identify additional
trials for inclusion.
Data collection and analysis
Selection of studies
Two review authors (KG and LB) independently screened the titles
and abstracts of studies identified by the search for potential in-
clusion in the review, seeking full-text articles for any references
identified by at least one of the review authors as potentially rele-
vant. We selected trials for inclusion based on the full-text articles.
The excluded full-text references with reasons for their exclusion
are provided in the 'Characteristics of excluded studies' table. We
have also listed any ongoing trials identified primarily through the
search of the clinical trial registers for further follow-up in the 'Char-
acteristics of ongoing studies' table. We resolved any discrepancies
through discussion.
Data extraction and management
Three review authors (LB, ELT, and MC) independently extracted the
data below in a pre-piloted Microsoft Excel-based data extraction
form (after translation of non-English articles), ensuring that two
independent data extractions were performed for each trial. KG al-
so extracted data related to risk of bias and outcome data.
• Outcome data (for each outcome and for each intervention
group, whenever applicable):
* number of participants randomised;
* number of participants included for the analysis;
* number of participants with events for binary outcomes,
mean and standard deviation for continuous outcomes,
number of events and the mean follow-up period for count
outcomes, and number of participants with events and the
mean follow-up period for time-to-event outcomes;
* natural logarithm of hazard ratio and its standard error if this
was reported rather than the number of participants with
events and the mean follow-up period for time-to-event out-
comes;
* definition of outcomes or scale used, if appropriate.
• Data on potential effect modifiers:
* participant characteristics such as age, sex, definition and
type of hepatorenal syndrome (type I or type II), the aetiolo-
gy for cirrhosis, and the interval between diagnosis of hepa-
torenal syndrome and treatment;
* details of the intervention and control (including dose, fre-
quency, and duration);
* length of follow-up;
* information related to 'Risk of bias' assessment (see Assess-
ment of risk of bias in included studies).
• Other data:
* year and language of publication;
* country in which the participants were recruited;
* year(s) in which the trial was conducted;
* inclusion and exclusion criteria.
We collected outcomes at maximum follow-up, but also at short-
term follow-up (up to three months) and medium-term follow-up
(from three months to five years) if applicable.
We attempted to contact the trial authors in the case of unclear
or missing information. If there was any doubt as to whether trials
shared the same participants, completely or partially (by identify-
ing common authors and centres), we attempted to contact the tri-
al authors to clarify whether the trial report was duplicated. Any
differences in opinion between the review authors were resolved
through discussion.
Assessment of risk of bias in included studies
We followed the guidance in the Cochrane Handbook for Systematic
Reviews of Interventions and that were described in the Cochrane
Hepato-Biliary Group Module to assess the risk of bias in included
trials (Higgins 2011; Gluud 2018). Specifically, we assessed sources
of bias as defined below (Schulz 1995; Moher 1998; Kjaergard 2001;
Wood 2008; Savović 2012a; Savović 2012b; Savović 2018).
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Allocation sequence generation
• Low risk of bias: the study authors performed sequence gener-
ation using computer random number generation or a random
number table. Drawing lots, tossing a coin, shuffling cards, and
throwing dice are adequate if performed by an independent per-
son not otherwise involved in the study. In general, we classified
the risk of bias as low if the method used for allocation conceal-
ment suggested that it was extremely likely that the sequence
was generated randomly (e.g. the use of an interactive voice re-
sponse system).
• Unclear risk of bias: the study authors did not specify the
method of sequence generation.
• High risk of bias: the sequence generation method was not ran-
dom.
Allocation concealment
• Low risk of bias: the participant allocations could not have been
foreseen in advance of, or during, enrolment. A central and inde-
pendent randomisation unit controlled allocation. The investi-
gators were unaware of the allocation sequence (e.g. if the allo-
cation sequence was hidden in sequentially numbered, opaque,
and sealed envelopes).
• Unclear risk of bias: the study authors did not describe the
method used to conceal the allocation so that the intervention
allocations may have been foreseen before, or during, enrol-
ment.
• High risk of bias: it is likely that the investigators who assigned
the participants knew the allocation sequence. We excluded
such quasi-randomised studies.
Blinding of participants and personnel
• Low risk of bias: any of the following: blinding of participants
and key study personnel ensured, and it was unlikely that the
blinding could have been broken; or, rarely, no blinding or in-
complete blinding, but the review authors judged that the out-
come was not likely to be influenced by lack of blinding.
• Unclear risk of bias: any of the following: insufficient information
to permit judgement of 'low risk' or 'high risk'; or the trial did not
address this outcome.
• High risk of bias: any of the following: no blinding or incomplete
blinding, and the outcome was likely to be influenced by lack
of blinding; or blinding of key study participants and personnel
attempted, but likely that the blinding could have been broken,
and the outcome was likely to be influenced by lack of blinding.
Blinded outcome assessment
• Low risk of bias: any of the following: blinding of outcome as-
sessment ensured, and unlikely that the blinding could have
been broken; or, rarely, no blinding of outcome assessment, but
the review authors judged that the outcome measurement was
not likely to be influenced by lack of blinding.
• Unclear risk of bias: any of the following: insufficient information
to permit judgement of 'low risk' or 'high risk'; or the trial did not
address this outcome.
• High risk of bias: any of the following: no blinding of outcome
assessment, and the outcome measurement was likely to be in-
fluenced by lack of blinding; or blinding of outcome assessment,
but likely that the blinding could have been broken, and the out-
come measurement was likely to be influenced by lack of blind-
ing.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make treatment
effects depart from plausible values. The study used sufficient
methods, such as multiple imputation, to handle missing data.
• Unclear risk of bias: there was insufficient information to assess
whether missing data in combination with the method used to
handle missing data were likely to induce bias in the results.
• High risk of bias: the results were likely to be biased due to miss-
ing data.
Selective outcome reporting
• Low risk of bias: the trial reported the following predefined out-
comes related to the main reason for treatment of people with
hepatorenal syndrome, namely, mortality, resolution of hepa-
torenal syndrome, and adverse events. If the original trial proto-
col was available, the outcomes should have been those called
for in that protocol. If the trial protocol was obtained from a tri-
al registry (e.g. ClinicalTrials.gov), the outcomes sought should
have been those enumerated in the original protocol if the trial
protocol was registered before or at the time that the trial was
begun. If the trial protocol was registered after the trial was be-
gun, those outcomes were not considered reliable.
• Unclear risk of bias: not all predefined, or clinically relevant and
reasonably expected, outcomes were reported fully, or it was
unclear whether data on these outcomes were recorded or not.
• High risk of bias: one or more predefined or clinically relevant
and reasonably expected outcomes were not reported, despite
the fact that data on these outcomes should have been available
and even recorded.
Other bias
• Low risk of bias: the trial appeared to be free of other compo-
nents that could put it at risk of bias (e.g. inappropriate control
or dose or administration of control, baseline differences, early
stopping).
• Unclear risk of bias: the trial may or may not have been free of
other components that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that could
put it at risk of bias (e.g. baseline differences, early stopping).
We considered a trial to be at low risk of bias if we assessed the tri-
al to be at low risk of bias across all listed 'Risk of bias' domains.
Otherwise, we considered trials to be at high risk of bias. At the out-
come level, we classified an outcome to be at low risk of bias if the
allocation sequence generation; allocation concealment; blinding
of participants, healthcare professionals, and outcome assessors;
incomplete outcome data; and selective outcome reporting (at the
outcome level) were at low risk of bias for objective and subjective
outcomes (Savović 2018).
Measures of treatment e:ect
Relative treatment eects
For dichotomous variables (e.g. the proportion of participants with
serious adverse events or any adverse event), we calculated the
odds ratio (OR) with 95% credible interval (CrI) (or Bayesian con-
fidence interval) (Severini 1993). For continuous variables (e.g.
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length of hospital stay), we calculated the mean difference (MD)
with 95% Crl. We planned to use standardised mean difference
(SMD) values with 95% Crl for health-related quality of life if the in-
cluded trials used different scales. We planned to obtain the final
scores, whenever possible. For count outcomes (e.g. number of se-
rious adverse events or number of any adverse event), we calculat-
ed the rate ratio (RaR) with 95% Crl. This assumes that the events
are independent of each other, i.e. if a person has had an event,
they are not at an increased risk of further outcomes, which is the
assumption in Poisson likelihood. For time-to-event data (e.g. all-
cause mortality at maximal follow-up), we calculated the hazard
ratio (HR) with 95% Crl.
Relative ranking
We estimated the ranking probabilities with 95% CrI for all interven-
tions of being at each possible rank for each intervention. We ob-
tained the surface under the cumulative ranking curve (SUCRA) (cu-
mulative probability), rankogram, and relative ranking table with
CrI for the ranking probabilities (Salanti 2011; Chaimani 2013).
Unit of analysis issues
The unit of analysis was the participant undergoing treatment
for hepatorenal syndrome according to the intervention group to
which the participant was randomly assigned.
Cluster-randomised clinical trials
In case of cluster-randomised clinical trials, we planned to include
cluster-randomised clinical trials, provided that the effect estimate
adjusted for cluster correlation was available, or if there was suf-
ficient information available to calculate the design effect (which
would allow us to take clustering into account). We also planned to
assess additional domains of risk of bias for cluster-randomised tri-
als according to guidance in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
Cross-over randomised clinical trials
In the case of cross-over randomised clinical trials, we planned to
include only the outcomes after the period of first intervention be-
cause the included treatments could have residual effects.
Trials with multiple intervention groups
We collected data for all trial intervention groups that met the inclu-
sion criteria. The codes for analysis that we used accounted for the
correlation between the effect sizes from studies with more than
two groups.
Dealing with missing data
We performed an intention-to-treat analysis, whenever possible
(Newell 1992); otherwise, we used the data available to us. When
intention-to-treat analysis is not used and the data are not missing
at random (for example, treatment was withdrawn due to adverse
events or duration of treatment was shortened because of lack of
response and such participants were excluded from analysis), this
can lead to biased results; therefore, we conducted best-worst case
scenario analysis (assuming a good outcome in intervention group
and bad outcome in control group) and worst-best case scenario
analysis (assuming a bad outcome in intervention group and good
outcome in control group) as sensitivity analyses, whenever possi-
ble, for binary and time-to-event outcomes, where binomial likeli-
hood was used.
For continuous outcomes, we imputed the standard deviation from
P values, according to guidance in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). If the data were
likely to be normally distributed, we planned to use the median
for meta-analysis when the mean was not available; otherwise, we
planned to simply provide a median and interquartile range of the
difference in medians. If the data were likely to be normally distrib-
uted and it was not possible to calculate the standard deviation
from the P value or the confidence intervals, we planned to impute
the standard deviation using the largest standard deviation in oth-
er trials for that outcome. This form of imputation can decrease the
weight of the study for calculation of mean differences and may
bias the effect estimate to no effect for calculation of standardised
mean differences (Higgins 2011).
Assessment of heterogeneity
We assessed clinical and methodological heterogeneity by careful-
ly examining the characteristics and design of included trials. We
planned to assess the presence of clinical heterogeneity by com-
paring effect estimates (see Subgroup analysis and investigation of
heterogeneity) in trial reports of different drug dosages, different
types of hepatorenal syndrome (type I and type II), different aeti-
ologies for cirrhosis (e.g. alcohol-related liver disease, viral liver dis-
eases, autoimmune liver disease), and based on the co-interven-
tions (e.g. both groups receive prophylactic antibiotics to decrease
the risk of subacute bacterial peritonitis). Different study designs
and risk of bias can contribute to methodological heterogeneity.
We assessed statistical heterogeneity by comparing the results
of the fixed-effect model meta-analysis and the random-effects
model meta-analysis, between-study variance (tau2 and compar-
ing this with values reported in the study of the distribution of
between-study heterogeneity) (Turner 2012), and by calculating I2
(Jackson 2014) using Stata/SE 15.1. If we identified substantial clin-
ical, methodological, or statistical heterogeneity, we planned to ex-
plore the heterogeneity and address it in subgroup analysis (see
Subgroup analysis and investigation of heterogeneity).
Assessment of transitivity across treatment comparisons
We assessed the transitivity assumption by comparing the distrib-
ution of the potential effect modifiers (clinical: type of hepatorenal
syndrome (type I versus type II); methodological: risk of bias, year
of randomisation, duration of follow-up) across the different pair-
wise comparisons.
Assessment of reporting biases
For the network meta-analysis, we planned to perform a compari-
son-adjusted funnel plot. However, to interpret a comparison-ad-
justed funnel plot, it is necessary to rank the studies in a meaning-
ful way, as asymmetry may be due to small sample sizes in new-
er studies (comparing newer treatments with older treatments) or
higher risk of bias in older studies (comparing older treatments
with placebo) (Chaimani 2012). As there was no meaningful way in
which to rank these studies (i.e. there was no specific change in the
risk of bias in the studies, sample size, or the control group used
over time), we judged the reporting bias by the completeness of the
search (Chaimani 2012).
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Data synthesis
Methods for indirect and mixed comparisons
We conducted network meta-analyses to compare multiple inter-
ventions simultaneously for each of the primary and secondary out-
comes. Network meta-analysis combines direct evidence within tri-
als and indirect evidence across trials (Mills 2012). We obtained a
network plot to ensure that the trials were connected by interven-
tions using Stata/SE 15.1 (Chaimani 2013). We excluded any trials
that were not connected to the network from the network meta-
analysis and reported only the direct pairwise meta-analysis for
such comparisons. We summarised the population and method-
ological characteristics of the trials included in the network meta-
analysis in a table based on pairwise comparisons. We conducted
a Bayesian network meta-analysis using the Markov chain Monte
Carlo method in OpenBUGS 3.2.3 as per guidance from the Na-
tional Institute for Health and Care Excellence (NICE) Decision Sup-
port Unit (DSU) documents (Dias 2016). We modelled the treat-
ment contrast (i.e. log odds ratio for binary outcomes, mean dif-
ference or standardised mean difference for continuous outcomes,
log rate ratio for count outcomes, and log hazard ratio for time-
to-event outcomes) for any two interventions ('functional parame-
ters') as a function of comparisons between each individual inter-
vention and the reference group ('basic parameters') using appro-
priate likelihood functions and links (Lu 2006). We used binomial
likelihood and logit link for binary outcomes, Poisson likelihood
and log link for count outcomes, binomial likelihood and comple-
mentary log-log link for time-to-event outcomes (a semiparametric
model which excludes censored individuals from the denominator
of ‘at risk’ individuals at the point when they are censored), and nor-
mal likelihood and identity link for continuous outcomes. We used
albumin plus terlipressin as the reference group as this was the
commonest intervention across the trials. We performed a fixed-ef-
fect model and random-effects model for the network meta-analy-
sis. We have reported both models for comparison with the refer-
ence group in a forest plot. For each pairwise comparison in a table,
we reported the fixed-effect model if the two models reported sim-
ilar results; otherwise, we reported the most conservative model.
We used a hierarchical Bayesian model using three different sets of
initial values to start the simulation-based parameter estimation,
employing codes provided by NICE DSU (Dias 2016). We used a nor-
mal distribution with large variance (10,000) for treatment effect
priors (vague or flat priors) centred at no effect. For the random-ef-
fects model, we used a prior distributed uniformly (limits: 0 to 5)
for the between-trial standard deviation and assumed this variabil-
ity would be the same across treatment comparisons (Dias 2016).
We used a 'burn-in' of 30,000 iterations, checked for convergence
(of effect estimates and between-study heterogeneity) visually (i.e.
whether the values in different chains mix very well by visualisa-
tion), and ran the models for another 30,000 simulations to obtain
effect estimates. If we did not obtain convergence, we increased
the number of simulations for the 'burn-in' and use the 'thin' and
'over relax' functions to decrease the autocorrelation. If we still did
not obtain convergence, we used alternate initial values and priors
employing methods suggested by Van Valkenhoef 2012. We also es-
timated the probability that each intervention ranks at each of the
possible positions using the NICE DSU codes (Dias 2016).
Assessment of inconsistency
We assessed inconsistency (statistical evidence of the violation
of transitivity assumption) by fitting both an inconsistency mod-
el and a consistency model. We used the inconsistency models
employed in the NICE DSU manual, as we used a common be-
tween-study standard deviation (Dias 2014). In addition, we used
a design-by-treatment full interaction model and planned to cre-
ate inconsistency factor (IF) plots to assess inconsistency (Higgins
2012; Chaimani 2013). Where possible, we created inconsistency
factor plots using Stata/SE 15.1. In the presence of inconsistency,
we planned to assess whether the inconsistency was due to clini-
cal or methodological heterogeneity by performing separate analy-
ses for each of the different subgroups mentioned in the Subgroup
analysis and investigation of heterogeneity section.
If there was evidence of inconsistency, we planned to identify areas
in the network where substantial inconsistency might be present in
terms of clinical and methodological diversities between trials and,
when appropriate, limit network meta-analysis to a more compat-
ible subset of trials.
Direct comparison
We performed the direct comparisons using the same codes and
the same technical details.
Subgroup analysis and investigation of heterogeneity
We planned to assess the differences in the effect estimates be-
tween the following subgroups and investigate heterogeneity and
inconsistency using meta-regression with the help of the codes pro-
vided in NICE DSU guidance (Dias 2012a), if we included a sufficient
number of trials (when there were at least two trials in at least two
of the subgroups) and when the interaction term could be calculat-
ed. We planned to use the following trial-level covariates for meta-
regression.
• Trials at low risk of bias compared to trials at high risk of bias.
• Based on the type of hepatorenal syndrome (type I versus type
II).
• Based on the aetiology for cirrhosis (e.g. alcohol-related liver
disease, viral liver diseases, autoimmune liver disease).
• Based on the interval between the diagnosis of hepatorenal syn-
drome and the start of treatment (less than or equal to one-week
interval between diagnosis and start of treatment versus more
than one week between diagnosis and start of treatment).
• Based on the co-interventions (e.g. both groups received pro-
phylactic antibiotics to decrease the risk of subacute bacterial
peritonitis).
• Based on the period of follow-up (short-term: up to three
months; medium-term: more than three months to five years;
long-term: more than five years).
• Based on the definition used by authors for serious adverse
events and any adverse events (ICH-GCP 1997 compared to oth-
er definitions).
We calculated a single common interaction term (which assumes
each relative treatment effect versus a common comparator treat-
ment is impacted in the same way by the covariate in question),
when applicable (Dias 2012a). If the 95% Crls of the interaction term
did not overlap zero, we considered this statistically significant het-
erogeneity or inconsistency (depending upon the factor being used
as a covariate).
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Sensitivity analysis
If there were post-randomisation dropouts, we reanalysed the
results using the best-worst case scenario and worst-best case
scenario as sensitivity analyses, whenever possible. We also per-
formed a sensitivity analysis excluding the trials in which mean or
standard deviation, or both were imputed, and use of the median
standard deviation in the trials to impute missing standard devia-
tions.
Presentation of results
We followed the PRISMA-NMA statement while reporting our re-
sults (Hutton 2015). We presented the effect estimates with 95% CrI
for each pairwise comparison calculated from the direct compar-
isons and network meta-analysis. We originally planned to present
the cumulative probability of the treatment ranks (i.e. the proba-
bility that the intervention is within the top two, the probability
that the intervention is within the top three, etc.) in graphs (SU-
CRA) (Salanti 2011). We plotted the probability that each interven-
tion was best, second best, third best, etc. for each of the different
outcomes (rankograms), which are generally considered more in-
formative (Salanti 2011; Dias 2012b) and ranking probability tables
with CrI, but we did not present these because of the sparse data
which can lead to misinterpretation of results due to large uncer-
tainty in the rankings (the CrI was 0 to 1 for all the ranks). We up-
loaded all the raw data and the codes used for analysis in The Eu-
ropean Organization for Nuclear Research open source database
(Zenodo): the link is: https://doi.org/10.5281/zenodo.3256099.
Grading of evidence
We presented 'Summary of findings' tables for all the primary
and secondary outcomes (see Primary outcomes; Secondary out-
comes) (Summary of findings for the main comparison; Summary
of findings 2). We followed the approach suggested by Yepes-Nunez
and colleagues (Yepes-Nunez 2019). First, we calculated the direct
and indirect effect estimates (when possible) and 95% Crl using the
node-splitting approach (Dias 2010), that is, calculating the direct
estimate for each comparison by including only trials in which there
was direct comparison of interventions and the indirect estimate
for each comparison by excluding the trials in which there was di-
rect comparison of interventions (and ensuring a connected net-
work). Next, we rated the quality of direct and indirect effect es-
timates using GRADE methodology which takes into account the
risk of bias, inconsistency (heterogeneity), directness of evidence
(including incoherence, the term used in GRADE methodology for
inconsistency in network meta-analysis), imprecision, and publi-
cation bias (Guyatt 2011). We then presented the relative and ab-
solute estimates of the meta-analysis with the best certainty of ev-
idence (Yepes-Nunez 2019). We also presented the 'Summary of
findings' tables in a second format presenting all the outcomes for
selected interventions (Yepes-Nunez 2019): we selected the three
interventions (albumin plus terlipressin, albumin plus noradrena-
line, and albumin alone) which were compared in the most trials
(Table 1; Table 2; Table 3; Table 4; Table 5).
Recommendations for future research
We provided recommendations for future research in the popu-
lation, intervention, control, outcomes, period of follow-up, and
study design based on the uncertainties that we identified in the
existing research.
R E S U L T S
Description of studies
Results of the search
We identified 1873 references through electronic searches of CEN-
TRAL (n = 291), MEDLINE (n = 654), Embase (n = 343), Science Ci-
tation Index Expanded (n = 531), World Health Organization Inter-
national Clinical Trials Registry Platform (n = 33), and ClinicalTri-
als.gov (n = 21). We did not identify any new eligible study from
EMA or FDA searches. After removing 492 duplicates, we obtained
1381 references. We then excluded 1303 clearly irrelevant refer-
ences through screening titles and reading abstracts and retrieved
78 references for further assessment. We identified no references
through scanning reference lists of the identified randomised tri-
als. We excluded 30 references (28 studies) for the reasons stated
in the Characteristics of excluded studies table. Two ongoing tri-
als identified through ClinicalTrials.gov did not report interim da-
ta (NCT02770716; NCT03455322). A total of 46 references (describ-
ing 25 trials) met the inclusion criteria. The reference flow is sum-
marised in the study flow diagram (Figure 2).
 
Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
21
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 2.   Study flow diagram.
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Figure 2.   (Continued)
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Included studies
A total of 25 trials met the inclusion criteria for and were included
in this review. A total of 1263 participants from these trials were
randomised to different interventions. The number of participants
ranged from 12 to 196. A total of 1185 participants from 23 trials pro-
vided data for one of more outcomes (Daskalopoulos 1985; Mitzn-
er 2000; Chelarescu 2003; Solanki 2003; Alessandria 2007; Goy-
al 2008; Martin-Llahi 2008; Neri 2008; Sanyal 2008; Sharma 2008;
Singh 2012; Tavakkoli 2012; Zafar 2012; Badawy 2013; Copaci 2013;
Ghosh 2013; Indrabi 2013; Cavallin 2015; Boyer 2016; Goyal 2016;
Arora 2018; Saif 2018; Stine 2018). Participant age ranged from 42 to
60 years and the proportion of females ranged from 5.8% to 61.5%
in the trials that reported this information. Seven trials included
both participants with hepatorenal syndrome type I and hepatore-
nal syndrome type II (Alessandria 2007; Goyal 2008; Martin-Llahi
2008; Tavakkoli 2012; Zafar 2012; Copaci 2013; Cavallin 2015), one
trial included participants with only hepatorenal syndrome type II
(Ghosh 2013), 13 included participants with only hepatorenal syn-
drome type I (Mitzner 2000; Solanki 2003; Neri 2008; Sanyal 2008;
Sharma 2008; Singh 2012; Badawy 2013; Indrabi 2013; Boyer 2016;
Goyal 2016; Arora 2018; Saif 2018; Stine 2018), and four trials did not
state the type of hepatorenal syndrome (Daskalopoulos 1985; Yang
2001; Chelarescu 2003; Koch 2016). No study explicitly stated only
including participants with a single cause of cirrhosis from alcohol,
viral, or autoimmune-related cirrhosis. All trials had two interven-
tion groups. We identified no cluster-randomised trials.
The follow-up in the trials ranged from one week to six months
(Table 2). The interventions, controls, number of included partici-
pants, potential effect modifiers, and reported follow-up period for
the different trials are provided in Table 2.
Overall, no systematic clinical or methodological differences be-
tween any of the comparisons seemed to exist. None of the trials
used 'no treatment' as a control group.
Funding: Two trials were funded by pharmaceutical companies
(Boyer 2016; Sanyal 2008); five trials did not receive funding from
pharmaceutical companies (Alessandria 2007; Arora 2018; Mar-
tin-Llahi 2008; Stine 2018; Tavakkoli 2012), and the remaining 18 tri-
als did not report the source of funding.
Any available further details of each study can be found in the Char-
acteristics of included studies section.
Excluded studies
The reasons for exclusion are provided in the Characteristics of
excluded studies table. Two trials had cross-over design, but had
very short duration of the intervention and short or no wash-out
periods; these were excluded because no meaningful data can be
obtained from these studies (Hadengue 1998; Pomier-Layrargues
2003). None of the remaining trials were randomised clinical trials.
Risk of bias in included studies
The risk of bias is summarised in Figure 3, Figure 4, and Table 3. Only
one trial was considered to be at low risk of bias in all the domains
(Sanyal 2008). The remaining trials were at unclear or high risk of
bias in one or more domains and were considered to be at high risk
of bias.
 
Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 4.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 4.   (Continued)
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Allocation
Twelve trials were at low risk of bias due to random sequence gen-
eration (Boyer 2016; Cavallin 2015; Ghosh 2013; Goyal 2016; Mar-
tin-Llahi 2008; Mitzner 2000; Neri 2008; Saif 2018; Sanyal 2008; Shar-
ma 2008; Singh 2012; Solanki 2003); the remaining trials were at
unclear risk of bias due to random sequence generation (Alessan-
dria 2007; Arora 2018; Badawy 2013; Chelarescu 2003; Copaci 2013;
Daskalopoulos 1985; Goyal 2008; Indrabi 2013; Koch 2016; Stine
2018; Tavakkoli 2012; Yang 2001; Zafar 2012). Seven trials were at
low risk of bias due to allocation concealment (Arora 2018; Boy-
er 2016; Cavallin 2015; Martin-Llahi 2008; Mitzner 2000; Neri 2008;
Sanyal 2008); the remaining trials were at unclear risk of bias due to
allocation concealment (Alessandria 2007; Badawy 2013; Chelares-
cu 2003; Copaci 2013; Daskalopoulos 1985; Ghosh 2013; Goyal 2008;
Goyal 2016; Indrabi 2013; Koch 2016; Saif 2018; Sharma 2008; Singh
2012; Solanki 2003; Stine 2018; Tavakkoli 2012; Yang 2001; Zafar
2012). Overall, six trials were at low risk of selection bias (Boyer
2016; Martin-Llahi 2008; Mitzner 2000; Neri 2008; Sanyal 2008).
Blinding
Three trials were at low risk of bias of performance bias and detec-
tion bias (Boyer 2016; Sanyal 2008; Stine 2018); nine trials were at
high risk of bias due to lack of blinding of participants and health
professionals and bias due to lack of blinding of outcome asses-
sors (Alessandria 2007; Arora 2018; Badawy 2013; Ghosh 2013; Goy-
al 2008; Goyal 2016; Martin-Llahi 2008; Sharma 2008; Singh 2012);
one trial was at high risk of bias due to blinding of participants and
health professionals, but unclear risk of bias due to lack of blinding
of outcome assessors (Solanki 2003); the remaining trials were at
unclear risk of bias due to lack of blinding of participants and health
professionals and bias due to lack of blinding of outcome asses-
sors (Cavallin 2015; Chelarescu 2003; Copaci 2013; Daskalopoulos
1985; Indrabi 2013; Koch 2016; Mitzner 2000; Neri 2008; Saif 2018;
Tavakkoli 2012; Yang 2001; Zafar 2012).
Incomplete outcome data
Thirteen trials were at low risk of incomplete outcome data (attri-
tion bias) (Alessandria 2007; Arora 2018; Boyer 2016; Goyal 2016;
Indrabi 2013; Martin-Llahi 2008; Neri 2008; Saif 2018; Sanyal 2008;
Sharma 2008; Solanki 2003; Stine 2018; Tavakkoli 2012); three tri-
als were at high risk of incomplete outcome data (attrition bias)
(Badawy 2013; Cavallin 2015; Daskalopoulos 1985); the remaining
trials were at unclear risk of incomplete outcome data (attrition
bias) (Chelarescu 2003; Copaci 2013; Ghosh 2013; Goyal 2008; Koch
2016; Mitzner 2000; Singh 2012; Yang 2001; Zafar 2012).
Selective reporting
We did not find a published protocol for any of the trials. Seven tri-
als were at low risk of selective reporting (reporting bias) as they re-
ported all-cause mortality, adverse events, and recovery from he-
patorenal syndrome (Arora 2018; Boyer 2016; Cavallin 2015; Ghosh
2013; Goyal 2016; Martin-Llahi 2008; Sanyal 2008); the remaining
trials were at unclear risk of selective reporting (reporting bias)
(Alessandria 2007; Badawy 2013; Chelarescu 2003; Copaci 2013;
Daskalopoulos 1985; Goyal 2008; Indrabi 2013; Koch 2016; Mitzner
2000; Neri 2008; Saif 2018; Sharma 2008; Singh 2012; Solanki 2003;
Stine 2018; Tavakkoli 2012; Yang 2001; Zafar 2012).
Other potential sources of bias
All trials were at low risk of other bias.
E:ects of interventions
See: Summary of findings for the main comparison; Summary of
findings 2
The network plot for all outcomes for which network meta-analy-
sis was performed is shown in Figure 1. If NMA was not performed,
the reason for not performing the NMA is reported under the out-
come. The model fit is available in Table 4. When we have report-
ed the fixed-effect model, the use of the random-effects model did
not alter the interpretation of results. The forest plots for the two
outcomes (all-cause mortality and recovery from hepatorenal syn-
drome) where the fixed-effect model and random-effects model re-
sulted in different interpretations are shown in Figure 5.
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Figure 5.   The forest plots for all-cause mortality and recovery from hepatorenal syndrome for which fixed-e:ect
model and random-e:ects model showed di:erent results. The more conservative random-e:ects model was used
for interpretation. Abbreviations: Alb = albumin
Mid = midodrine
Nor = noradrenaline
Oct = Octreotide
Pen = Pentoxyfylline
Ter = Terlipressin
 
Inconsistency
Only two outcomes (all-cause mortality at maximal follow-up and
resolution of hepatorenal syndrome at maximal follow-up) had tri-
angular or quadrangular closed loops to allow assessment of incon-
sistency. There was no evidence of inconsistency as indicated by
deviance information criterion (DIC) for these two outcomes, as in-
dicated in Table 4. However, the Inconsistency Factor plot showed
that there was inconsistency in the recovery from hepatorenal syn-
drome (Inconsistency Factor: 2.57; 95% CrI 0.24 to 4.91), although
there was no evidence of inconsistency in mortality at maximal fol-
low-up (Figure 6). We were unable to obtain convergence for de-
sign-by-treatment results for either of the outcomes, despite the
different measures such as altering the initial values and giving dif-
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ferent prior distributions as described above; probably because of
the complex model with sparse data.
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Figure 6.   Inconsistency Factor (IF) plot showing that there was no evidence of inconsistency for all-cause mortality,
but there was inconsistency for recovery from hepatorenal syndrome, the two outcomes for which inconsistency
could be assessed. All-cause mortality: direct estimate The X-axis shows the di:erence in the direct and indirect
e:ect estimates.
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Probability ranks
The 95% CrI of the probability ranks were wide and included 0 and
1 in all the comparisons for all the outcomes. This was probably
because of the sparse data from small trials. Therefore, we did not
present the ranking probabilities (in a table), rankograms, and SU-
CRA plots: we considered that presenting this information would
be unhelpful and potentially misleading and would ignore the sys-
tematic errors in the trials. However, we have presented the medi-
an probability ranks, when possible, in the Summary of findings for
the main comparison and Summary of findings 2.
Certainty of evidence
The overall certainty of the evidence was low or very low for all out-
comes. The main reasons for this were the trials at high risk of bias,
in particular, lack of blinding; small sample size; and imprecision.
There was also heterogeneity as the fixed-effect and random-ef-
fects models gave different interpretations for all-cause mortali-
ty and recovery from hepatorenal syndrome. For network meta-
analysis, there was no evidence of inconsistency in terms of model
fit for the two outcomes (all-cause mortality and recovery from he-
patorenal syndrome), where it was possible to compare the direct
and indirect evidence. There was no evidence of inconsistency by
inconsistency factor plot for all-cause mortality. However, the in-
consistency factor plot indicated inconsistency (Inconsistency Fac-
tor: 2.57; 95% CrI 0.24 to 4.91) and point effect estimates were in
different directions for direct comparison and indirect comparison
for recovery from hepatorenal syndrome; therefore, the results of
network meta-analysis may indicate inconsistency and should be
interpreted with caution. The summary of findings and certainty of
evidence is available in Summary of findings for the main compar-
ison.
Mortality at maximal follow-up
Twenty-two trials (1153 participants) reported mortality at maxi-
mal follow-up (Daskalopoulos 1985; Mitzner 2000; Chelarescu 2003;
Solanki 2003; Alessandria 2007; Martin-Llahi 2008; Neri 2008; Sanyal
2008; Sharma 2008; Singh 2012; Tavakkoli 2012; Zafar 2012; Badawy
2013; Copaci 2013; Ghosh 2013; Indrabi 2013; Cavallin 2015; Boyer
2016; Goyal 2016; Arora 2018; Saif 2018; Stine 2018). A total of 12
treatments were compared in these 22 trials. A total of 19 trials (six
treatments) could be included in the network meta-analysis. Three
trials could not be included because they were not connected to the
network (Daskalopoulos 1985; Mitzner 2000; Chelarescu 2003). The
random-effects model was used as it had better model fit (Table 4)
and was more conservative. The between-study variance was 0.19
(95% CrI 0.05 to 0.70). There was no evidence of differences (equiv-
alent to statistically significant difference in frequentist analysis) in
any of the comparisons included in the network meta-analysis or
direct comparisons.
The comparisons in the three trials unconnected to the network
were as follows (Daskalopoulos 1985; Mitzner 2000; Chelarescu
2003).
• Octreotide versus captopril plus octreotide (Chelarescu 2003):
HR 2.73 (95% CrI 0.21 to 83.01).
• MARS (Molecular Adsorbent Recirculating System) versus
haemofiltration (Mitzner 2000): no convergence in the Bayesian
direct comparison analysis; all five participants who received
haemofiltration and 6/8 (75%) people who received MARS died
during the follow-up period.
• Surgical (peritoneovenous shunt) versus medical (no further de-
tails) (Daskalopoulos 1985): HR 0.63 (95% CrI 0.23 to 1.66).
Health-related quality of life
None of the trials reported health-related quality of life.
Serious adverse events
Three trials (428 participants) reported the proportion of people
with serious adverse events (Sanyal 2008; Boyer 2016; Arora 2018);
all were included in the network meta-analysis. Three treatments
were compared in these trials. The fixed-effect model was used.
There was no evidence of a difference in the network meta-analysis
or in the direct comparisons (Table 5).
Two trials (166 participants) reported number of serious adverse
events (Martin-Llahi 2008; Arora 2018); both were included in the
network meta-analysis. Three treatments were compared. Overall,
57 serious adverse events were reported in 166 participants (0.3 se-
rious adverse events per participant). The fixed-effect model was
used. There was no evidence of a difference in the network meta-
analysis or in the direct comparisons (Table 5).
Adverse events
Four trials (402 participants) reported the proportion of people
with any adverse events (Sanyal 2008; Ghosh 2013; Cavallin 2015;
Boyer 2016); all were included in the network meta-analysis. Four
treatments were compared. The fixed-effect model was used. There
was no evidence of a difference in the network meta-analysis or in
the direct comparisons (Table 5).
Five trials (293 participants) reported number of (any) adverse
events (Martin-Llahi 2008; Sharma 2008; Singh 2012; Goyal 2016;
Arora 2018); all were included in the network meta-analysis. Three
treatments were compared. The fixed-effect model was used. The
number of any adverse events were lower in albumin plus nora-
drenaline versus albumin plus terlipressin (rate ratio 0.51 (95% CrI
0.28 to 0.87) by direct comparison and rate ratio 0.50 (95% CrI 0.28
to 0.88) by network meta-analysis). There was no evidence of a dif-
ference in the remaining network meta-analysis or in the direct
comparisons (Table 5).
Liver transplantation
Four trials (342 participants) reported liver transplantation at max-
imal follow-up (Alessandria 2007; Sanyal 2008; Boyer 2016; Stine
2018). A total of five treatments were compared in these four tri-
als. Three trials (three treatments) could be included in the network
meta-analysis. The fixed-effect model was used. There was no evi-
dence of differences in any of the comparisons included in the net-
work meta-analysis or in the direct comparisons (Table 5).
One trial was not included in the network meta-analysis because it
was not connected to the network (Stine 2018). In this trial, there
was no evidence of a difference in the proportion of people who
underwent liver transplantation between albumin plus midodrine
plus octreotide plus pentoxifylline versus albumin plus midodrine
plus octreotide: HR 0.99 (95% CrI 0.02 to 38.59).
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Recovery from hepatorenal syndrome
None of the trials reported symptomatic recovery from hepatore-
nal syndrome (for example, recovery from oliguria or anuria or re-
covery from hepatorenal syndrome that required renal replace-
ment therapy). Eighteen trials (1047 participants) reported recov-
ery from hepatorenal syndrome (as per definition) at maximal fol-
low-up (Alessandria 2007; Goyal 2008; Martin-Llahi 2008; Neri 2008;
Sanyal 2008; Sharma 2008; Singh 2012; Tavakkoli 2012; Badawy
2013; Copaci 2013; Ghosh 2013; Indrabi 2013; Cavallin 2015; Boyer
2016; Goyal 2016; Arora 2018; Saif 2018; Stine 2018); all were includ-
ed in the network meta-analysis. Six treatments were compared.
The random-effects model was used as it had better model fit (Ta-
ble 4) and was more conservative. The between-study variance was
0.16 (95% CrI 0% to 0.86). In the direct comparisons, albumin plus
midodrine plus octreotide and albumin plus octreotide had low-
er recovery from hepatorenal syndrome than albumin plus terli-
pressin (HR 0.04; 95% CrI 0.00 to 0.25 and HR 0.26, 95% CrI 0.07 to
0.80 respectively). There was no evidence of differences between
the groups in any of the other direct comparisons. However, in the
network meta-analysis, albumin and albumin plus midodrine plus
octreotide had lower recovery from hepatorenal syndrome than al-
bumin plus terlipressin and albumin plus noradrenaline.
• Albumin versus albumin plus terlipressin: HR 0.28 (95% CrI 0.14
to 0.53)
• Albumin plus midodrine plus octreotide versus albumin plus ter-
lipressin: HR 0.26 (95% CrI 0.08 to 0.79)
• Albumin versus albumin plus noradrenaline: HR 0.33 (95% CrI
0.14 to 0.69)
• Albumin plus midodrine plus octreotide versus albumin plus no-
radrenaline: HR 0.30 (95% CrI 0.09 to 0.92)
There was no evidence of differences in any of the other compar-
isons in the network meta-analysis.
Other features of decompensation
None of the trials reported the proportion of people with one or
more features of decompensation. One trial (46 participants) re-
ported other features of decompensation at maximal follow-up
(Martin-Llahi 2008). A total of 42 decompensation events occurred
in these 46 participants (0.91 events per participant). There was no
evidence of a difference between albumin versus albumin plus ter-
lipressin: rate ratio 1.10 (95% CrI 0.60 to 2.03).
Length of hospital stay
None of the trials reported this outcome.
Number of days of lost work
None of the trials reported this outcome.
Treatment costs
Five trials (219 participants) reported costs (maximal follow-up)
(Alessandria 2007; Sharma 2008; Singh 2012; Badawy 2013; Saif
2018). All five trials compared albumin + terlipressin versus albu-
min + noradrenaline. We used an international exchange rate based
on purchasing power parities (PPP) to convert cost estimates to US
dollars (USD), and we used the gross domestic product (GDP) defla-
tors (or implicit price deflators for GDP) to convert cost estimates to
2017 USD using PPP conversion rates and GDP deflator values avail-
able from the International Monetary Fund in the World Economic
Outlook Database (www.imf.org/external/data.htm). The fixed-ef-
fect model was used. The cost of albumin plus noradrenaline was
lower (i.e. cheaper) than albumin plus terlipressin (USD -1066.00;
95% CrI -1093.00 to -1039.00).
Subgroup analyses
Because of the nature of the data (most trials included participants
with varied aetiology without separate outcome data based on ae-
tiology; and the presence of only one trial at low risk of bias), the on-
ly subgroup analysis performed was based on the type of hepatore-
nal syndrome. Even for type of hepatorenal syndrome, subgroup
analysis was possible only for mortality at maximal follow-up and
recovery from hepatorenal syndrome because of sparse data for
the remaining outcomes.
Although the interaction term did not overlap 0 for all-cause mor-
tality at maximal follow-up (interaction term -0.30 (95% CrI -0.57 to
-0.01), there was no evidence of differences in all-cause mortality
for any of the subgroups, i.e. hepatorenal syndrome type 1, hepa-
torenal syndrome type 2, or when this information was not avail-
able. However, the differences between the interventions versus al-
bumin plus terlipressin were generally larger in type II hepatorenal
syndrome than in other categories. The interaction term did over-
lap 0 for recovery of hepatorenal syndrome (interaction term 0.05
(95% CrI -0.45 to 0.61)).
Sensitivity analysis
The scenario analysis that we performed for post-randomisation
dropouts for binary and time-to-event outcomes (where binomial
likelihood was used) did not reveal any alterations in the results.
Excluding three trials in which the standard deviation was initially
imputed (Sharma 2008; Singh 2012; Saif 2018) for treatment costs,
did not alter our conclusions.
Assessment of reporting biases
Since there was no meaningful way in which to rank these studies
(i.e. there was no specific change in the risk of bias in the studies,
sample size, or the control group used over time), we did not per-
form the comparison-adjusted funnel plot.
D I S C U S S I O N
Summary of main results
We included a total of 25 trials (1263 participants) in this review.
A total of 1185 participants from 23 trials were included in one
or more outcomes. Overall, 58.6% of participants died and about
35.3% of participants recovered from hepatorenal syndrome with-
in three months. There was no evidence of inconsistency based
on model fit in the two networks (mortality at maximal follow-up
and recovery from hepatorenal syndrome at maximal follow-up) in
which we could assess this. However, the Inconsistency Factor in-
dicated inconsistency, and the effect estimates from direct com-
parisons and indirect comparisons were not similar for recovery
from hepatorenal syndrome. Generally, the networks were sparse,
and they involved mostly comparisons between albumin plus ter-
lipressin, albumin plus noradrenaline, and albumin alone. There-
fore, the results from network meta-analysis should be interpret-
ed with caution. None of the trials included 'no treatment' as the
control group. Therefore, the effects of these treatments against no
treatment is not known. However, it is unlikely that patients with
hepatorenal syndrome are not treated in any fashion.
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There was no evidence of a difference for any of the treatments re-
garding the following outcomes: mortality at maximal follow-up,
serious adverse events (proportion), serious adverse events (num-
ber), any adverse events (proportion), liver transplantation at max-
imal follow-up, or other decompensation events. The number of
adverse events and costs were lower with albumin plus noradren-
aline than with albumin plus terlipressin. The implications of an
increased number of adverse events is unclear, as the impact of
these adverse events on the participant's health-related quality of
life was not reported by any of the trials. Albumin alone and albu-
min plus midodrine plus octreotide had lower recovery from hepa-
torenal syndrome than both albumin plus terlipressin and albumin
plus noradrenaline. However, these were hepatorenal syndrome as
per definitions and the impact of recovery from hepatorenal syn-
drome on clinical outcomes is not known.
Future trials can and should be powered on short-term all-cause
mortality. Albumin plus terlipressin and albumin plus noradrena-
line were the commonest interventions used in the trials and had
higher recovery from hepatorenal syndrome than albumin alone
and albumin plus midodrine plus octreotide. Thus, these two inter-
ventions seem to be the two interventions that should be compared
in future trials. The sample size required in such trials based on a
control group proportion of 52% (the weighted median mortality
proportion in albumin plus terlipressin), a relative risk reduction of
20% in the experimental group, type I error of 5%, and type II error
of 20% is 720 participants. It is important that health-related qual-
ity of life and adverse events (due to any cause: disease-related,
treatment-related, or co-morbidity-related) should be measured as
outcomes in such a trial. A short period of follow-up of 90 days may
be sufficient to determine the effectiveness of an intervention.
Overall completeness and applicability of evidence
The trials included people who had developed various aetiologies
of liver cirrhosis and included people with both type I and II hepa-
torenal syndrome. The findings of this review are, therefore, applic-
able to people undergoing treatment for either type I or II hepatore-
nal syndrome with any underlying liver cirrhosis aetiology. Howev-
er, we did not include trials in people who had previously under-
gone liver transplantation. Therefore, the findings of this review are
applicable only to people who had not previously undergone liver
transplantation.
Quality of the evidence
The overall quality (certainty) of the evidence was low or very low
for all outcomes. The main reasons for this were the trials at high
risk of bias, in particular, lack of blinding or inadequate blinding;
small sample size; and imprecision. There was also heterogeneity
as the fixed-effect and random-effects model gave different inter-
pretations for all-cause mortality and recovery from hepatorenal
syndrome. For network meta-analysis, there was no evidence of in-
consistency in terms of model fit for the two outcomes (all-cause
mortality and recovery from hepatorenal syndrome), where it was
possible to compare the direct and indirect evidence. However, the
Inconsistency Factor Plot indicated inconsistency and the point ef-
fect estimates were in different directions for direct comparison
and indirect comparison for recovery from hepatorenal syndrome;
therefore, the results of network meta-analysis may indicate incon-
sistency and should be interpreted with caution.
Potential biases in the review process
We selected a range of databases to search without using any lan-
guage restrictions and conducted the network meta-analysis ac-
cording to NICE DSU guidance (Dias 2016). In addition, we have
presented the results from the fixed-effect model and random-ef-
fects model and used the more conservative model. These are the
strengths of the review process.
We have excluded studies that compared variations in duration or
dose in the different interventions. Hence, this review does not pro-
vide information on whether one dose or duration of treatment is
better than another. Another major limitation of this review was the
paucity of data. Few trials were included for each comparison; in
many comparisons, only one trial was included. This makes it diffi-
cult to assess whether the effect estimates are reproducible. This
paucity of data decreases the confidence in the results.
All of the network meta-analyses included only sparse data from
trials at high risk of bias. We were able to compare the direct and
indirect estimates for very few comparisons. This means that the
tests for inconsistency are underpowered. One of the underpinning
assumptions of a network meta-analysis is that the participants in
the different comparisons are similar. There was no evidence of sys-
tematic differences across comparisons from clinical or method-
ological points of view. However, one cannot rule out violation of
the transitivity assumption because of the sparse data; potential
differences in the co-interventions, and potential differences in the
definitions used by trial authors for adverse events and serious ad-
verse events.
We only included randomised clinical trials, which are known to
focus mostly on benefits and do not collect and report harms in
a detailed manner. According to our choice of studies (i.e. only
randomised clinical trials), it is possible that we have missed a
large number of studies addressing reporting of harms. Accord-
ingly, this review is biased towards benefits ignoring harms. We
may have, therefore, overlooked evidence of harm from non-ran-
domised studies. On the other hand, inclusion of non-randomised
studies in the network meta-analysis can increase the differences
in potential modifiers and decrease the reliability of the findings of
the network meta-analysis.
Agreements and disagreements with other studies or
reviews
We agree with the findings of one Cochrane review and another
systematic review which found no evidence of benefit for albumin
plus terlipressin and very low-certainty evidence of increased ad-
verse events with albumin plus terlipressin versus albumin plus
noradrenaline (Israelsen 2017; Nassar Junior 2014). We also agree
with another Cochrane review that stated that albumin alone has
lower recovery from hepatorenal syndrome than albumin plus ter-
lipressin (Allegretti 2017). However, we do not agree that albumin
plus terlipressin decreases mortality: the probable reason for the
different interpretation is the trials included in the analysis. We
excluded one trial (Hadengue 1998) as this was a cross-over ran-
domised clinical trial with 48 hours of treatment and only 24 hours
of wash-out period because of concerns for residual effect; we also
considered two likely publications of the same trial, based on the
common authors included, the intervention, control, and partial
overlapping of recruitment period (Neri 2008). We were unable to
confirm whether these were one and the same trial or two different
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trials. Israelsen 2017 treated them as two different trials, while we
treated these as two different reports of the same trial (Neri 2008).
Other reasons could be different analyses methods used (for exam-
ple, no zero error correction in the Bayesian methods used in our
review versus frequentist method with zero correction with the de-
fault 0.5 added in Review Manager).
In another systematic review, Nanda and colleagues concluded
that intravenous infusion of terlipressin (in combination with albu-
min) is the most effective medical therapy for reversing hepatore-
nal syndrome (Nanda 2018). The possible reasons for disagreement
is that Nanda and colleagues did not take into account the risk of
bias in the trials and the information on adverse events was not tak-
en into account while arriving at those conclusions (Nanda 2018).
While we found that albumin plus terlipressin was better than albu-
min alone in terms of recovery from hepatorenal syndrome (based
on very low-certainty evidence), we did not find any evidence to
suggest that albumin plus terlipressin was better than albumin plus
noradrenaline in terms of recovery from hepatorenal syndrome.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Based on very low-certainty evidence, there is no evidence of ben-
efit or harm of any of the interventions for hepatorenal syndrome
with regards to the following outcomes: all-cause mortality, serious
adverse events (proportion), number of serious adverse events per
participant, any adverse events (proportion), liver transplantation,
or other decompensation events. Low-certainty evidence suggests
that albumin plus noradrenaline had fewer 'any adverse events per
participant' and costs than albumin plus terlipressin. Low- or very
low-certainty evidence also found that albumin plus midodrine
plus octreotide and albumin alone had lower recovery from hepa-
torenal syndrome compared with albumin plus terlipressin and al-
bumin plus noradrenaline.
Implications for research
Further well-designed randomised clinical trials are necessary.
Some aspects of the design of the randomised clinical trials are as
follows.
Study design: placebo-controlled, parallel, randomised clinical tri-
al
Participants: people with cirrhosis in whom hepatorenal syn-
drome has developed
Intervention: albumin plus noradrenaline
Control: albumin plus terlipressin
Outcomes:
Primary outcome: short-term mortality (90-day all-cause mortality)
Secondary outcomes: health-related quality of life, adverse events,
recovery from hepatorenal syndrome, and resource utilisation
measures including length of hospital stay
Minimum length of follow-up: 90 days
Sample size: Please see discussion
Trials need to be designed and conducted according to the SPIRIT
(Standard Protocol Items: Recommendations for Intervention-
al Trials) statement (Chan 2013) and reported according to the
CONSORT statement (Schulz 2010).
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Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 22
Post-randomisation dropouts: 0 (0%)
Revised sample size: 22
Average age: 55 years
Females: 6 (27.3%)
Hepatorenal syndrome type 1: 9 (40.9%)
Hepatorenal syndrome type 2: 13 (59.1%)
Alcoholic cirrhosis: 6 (27.3%)
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (example, PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
Years of recruitment: not stated
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: yes
Alcoholic cirrhosis: yes
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
Other causes for cirrhosis: not stated
Other important exclusion criteria
• Heart failure
• Respiratory failure
Alessandria 2007 
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• Coronary disease
• Peripheral artery disease
• Patients not considered eligible for improvement in renal function after blood volume expansion
Interventions Patients were randomly assigned to two groups.
Group 1: noradrenaline plus albumin (n = 10)
Further details: noradrenaline: continuous infusion at 0.1 μg/kg/min increased every 4 hours based on
arterial blood pressure in steps of 0.05 μg/kg/min up to a maximum dose of 0.7 μg/kg/min. Albumin:
given to maintain central venous pressure between 10 and 15 cm H2O
Group 2: terlipressin plus albumin (n = 12)
Futher details: terlipressin: intravenous bolus 1 mg every 4 hours, increased to 2 mg every 4 hours after
3 days of treatment if reduction of at least 25% serum creatinine not observed. Albumin: given to main-
tain central venous pressure between 10 and 15 cm H2O.
Outcomes The outcomes reported were:
• mortality
• liver transplantation
• recovery from HRS
• costs
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Randomization was made by using the sealed opaque envelopes
method"
Allocation concealment
(selection bias)
Unclear risk Quote: "Randomization was made by using the sealed opaque envelopes
method".
Comment: Further details were not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "Prospective, randomized, unblinded, pilot study"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "Prospective, randomized, unblinded, pilot study"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Alessandria 2007  (Continued)
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Methods Randomised clinical trial
Participants Country: India
Number randomised: 120
Post-randomisation dropouts: 0 (0%)
Revised sample size: 120
Average age: 40 years
Females: 7 (5.8%)
Patients with HRS type I: 120 (100%)
Patients with HRS type II: 0 (0%)
Alcoholic cirrhosis: 87 (72.5%)
Viral-related cirrhosis: 18 (15%)
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): 5 (4.2%)
Other causes for cirrhosis: 10 (8.3%)
Follow-up in months: 1
Years of recruitment: 2015-2016
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: no
Alcoholic cirrhosis: yes
Viral-related cirrhosis: yes
Autoimmune disease-related cirrhosis: yes
Other causes for cirrhosis: yes
Other important exclusion criteria
• Age < 18 years
• Decompensated cirrhosis
• Patients on renal replacement therapy
• Renal transplantation
• Liver transplantation
• History of coronary disease
• Ischaemic cardiomyopathy
• Ventricular arrhythmia
• Peripheral vascular disease
• Chronic kidney disease
• Obstructive uropathy
Interventions Patients were randomly assigned to two groups.
Group 1: noradrenaline plus albumin (n = 60)
Arora 2018 
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Further details: noradrenaline: continuous intravenous infusion starting at 0.5 mg/h with doubling of
dose up to 3 mg/h after every 4 hours designed to achieve an increase in mean arterial pressure of at
least 10 mmHg or an increase in 4 h urine output > 200 mL. Albumin 20-40 g/day given until the end of
reversal of hepatorenal syndrome acute kidney injury or evidence of volume overload (central venous
pressure > 18cm H2O or inferior vena cava > 22 mm) or requirement of renal replacement therapy.
Group 2: terlipressin plus albumin (n = 60)
Futher details: terlipressin: continuous infusion started at the dosage of 2 mg/24h. The dosage of terli-
pressin was doubled every 48 hours in case of non-response (< 25% of pretreatment value) to the max-
imum dosage of 12 mg/24h. Albumin 20-40 g/day given until the end of reversal of hepatorenal syn-
drome acute kidney injury or evidence of volume overload (central venous pressure > 18cm H2O or in-
ferior vena cava > 22 mm) or requirement of renal replacement therapy.
Outcomes The outcomes reported were:
• mortality
• serious adverse events
• adverse events
• recovery from HRS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: This information was not available.
Allocation concealment
(selection bias)
Low risk Quote: "Allocation concealment was done by sequentially numbered opaque
sealed envelopes (SNOSE) technique".
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "The study was conducted as a randomized open label trial".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "The study was conducted as a randomized open label trial".
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
Low risk Comment: No protocol was available, but the authors reported expected clini-
cal outcomes adequately.
Other bias Low risk Comment: No other bias noted
Arora 2018  (Continued)
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Number randomised: 60
Post-randomisation dropouts: 9 (15%)
Revised sample size: 51
Average age: 45 years
Females: 16 (31.4%)
Patients with HRS type I: 51 (100%)
Patients with HRS type II: 0 (0%)
Alcoholic cirrhosis: 5 (9.8%)
Viral-related cirrhosis: 47 (92.2%)
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): 7 (13.7%)
Other causes for cirrhosis: 11 (21.6%)
Follow-up in months: 0.5
Years of recruitment: 2009-2012
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: no
Alcoholic cirrhosis: yes
Viral-related cirrhosis: yes
Autoimmune disease-related cirrhosis: yes
Other causes for cirrhosis: yes
Other important exclusion criteria
• Multinodular hepatocellular carcinoma
• Septic shock
• Parenchymal kidney disease
• Peripheral vascular disease
• Coronary artery disease
• Heart failure
• Respiratory failure
• Previous myocardial infarction
• Hypersensitivity to any of the study medications
• Any contraindication for central venous line insertion
• Patients on nephrotoxic medications
• Pateints enrolled in another trial
• Pregnant women
• Lactating women
Interventions Patients were randomly assigned to two groups.
Group 1: noradrenaline plus albumin (n = 26)
Badawy 2013  (Continued)
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Further details: noradrenaline initial dose of 0.5 mg/hr by intravenous continuous infusion to revert
type 1 hepatorenal syndrome. If the target was not achieved, the norepinephrine dose was increased
stepwise by 0.5 mg/hr every 4 h until the maximum dose (3 mg/h) was reached. Norepinephrine infu-
sion was titrated guided by the mean arterial blood pressure. Mean arterial pressure was kept at a level
of 85-90 mmHg or less. Albumin 20% 200-400 g/day.
Group 2: terlipressin plus albumin (n = 25)
Futher details: terlipressin initial dose of 3 mg/24hr by intravenous continuous infusion. If during the
following 48 hr the hepatorenal syndrome did not revert, the dose was increased to 6 mg/24 hr. If the
hepatorenal syndrome reversal was not achieved within 48 hr, the dose of terlipressin was increased to
the maximal dose of 12 mg/24hr. Albumin 20% 200-400 g/day.
Outcomes The outcomes reported were:
• Mortality
• Recovery from HRS
• Costs
Notes Reasons for post-randomisation dropouts: Died within 72 hours
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Randomization was done by sealed envelopes".
Allocation concealment
(selection bias)
Unclear risk Quote: "Randomization was done by sealed envelopes".
Comment: Further details were not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "The treatment was not blinded".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "The treatment was not blinded".
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Comment: Patients who were dead within 72 hours were excluded: this was
highly likely to be related to the outcomes.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Badawy 2013  (Continued)
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Participants Country: United States & Canada
Number randomised: 196
Post-randomisation dropouts: 0 (0%)
Revised sample size: 196
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Average age: 55 years
Females: 77 (39.3%)
Hepatorenal syndrome type 1: 196 (100%)
Hepatorenal syndrome type 2: 0 (0%)
Alcohol-related cirrhosis: 103 (52.6%)
Viral-related cirrhosis: 85 (43.4%)
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): 9 (4.6%)
Other causes for cirrhosis: 55 (28.1%)
Follow-up in months: 3
Years of recruitment: 2010-2013
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: no
Alcoholic cirrhosis: yes
Viral-related cirrhosis: yes
Autoimmune disease-related cirrhosis: yes
Other causes for cirrhosis: yes
Other important exclusion criteria
• Serum creatinine level greater than 7 mg/dL
• Hypotension (MAP < 70 mmHg) with evidence of hypoperfusion
• Sepsis
• Untreated infection
• Evidence of other intrinsic renal disease
• Recent exposure (≥ 48 hours) to octreotide, midodrine, vasopressin, dopamine, or other vasopressors
Interventions Participants were randomly assigned to two groups.
Group 1: terlipressin and albumin (n = 97)
Further details: terlipressin 1 mg slow intravenous bolus injections over 2 minutes every 6 hours (to-
tal amount of terlipressin, 4 mg/day). If serum creatinine had decreased but not by more than 30%
from the baseline value on day 4 of treatment after a minimum of 10 doses, the dose was increased to 2
mg every 6 hours (total amount of terlipressin, 8 mg/day). Albumin 20-40 g/day as clinically indicated.
Treatment was continued until at least 2 serum creatinine values of 1.5 mg/dL or less were obtained at
least 40 hours apart (minimum of 22 hours apart in the event of transplant or hospital discharge)18 and
no more than 24 hours after the last dose, or up to 14 days (maximum of 15–16 days if serum creatinine
first reached 1.5 mg/dL on days 13–14, respectively). If serum creatinine was at or above the baseline
value on day 4 after a minimum of 10 doses, the study medication was discontinued. Treatment also
was discontinued for patients who had to undergo renal replacement therapy or liver transplantation.
Dosing was discontinued permanently if an ischaemic event occurred. If investigators judged it to be
potentially beneficial, patients with at least a 30% reduction in serum creatinine during initial treat-
ment and who developed recurrence of hepatorenal syndrome type I could be re-treated once with the
initially assigned study medication.
Group 2: albumin (n = 99)
Further details: placebo was administered via a slow intravenous bolus injection over 2 minutes every
6 hours (total amount of terlipressin, 4 mg/day). Detailed criteria for dose increases, re-treatment, and
discontinuation have been described in group 1.
Outcomes The outcomes reported were:
• Mortality
• Serious adverse events
Boyer 2016  (Continued)
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• Adverse events
• Liver transplantation
• Recovery from hepatorenal syndrome
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "by using a central interactive voice response system"
Allocation concealment
(selection bias)
Low risk Quote: "by using a central interactive voice response system"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "placebo-controlled, double-blind"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "placebo-controlled, double-blind"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
Low risk Comment: study protocol was available, and the authors have reported the ex-
pected clinical outcomes adequately.
Other bias Low risk Comment: No other bias noted
Boyer 2016  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 49
Post-randomisation dropouts: 1 (2%)
Revised sample size: 48
Average age: 62 years
Females: 16 (33.3%)
Hepatorenal syndrome type 1: 44 (91.7%)
Hepatorenal syndrome type 2: 4 (8.3%)
Alcohol-related cirrhosis: 0 (0%)
Viral-related cirrhosis: 18 (37.5%)
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
Follow-up in months: 3
Years of recruitment: 2008-2012
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Cavallin 2015 
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Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: yes
Alcoholic cirrhosis: no
Viral-related cirrhosis: yes
Autoimmune disease-related cirrhosis: not stated
Other causes for cirrhosis: yes
Other important exclusion criteria
• Hepatocellular carcinoma outside Milan criteria
• Septic shock
• Cardiac failure
• Respiratory failure
• Stroke
• Coronary artery disease
Interventions Participants were randomly assigned to two groups.
Group 1: terlipressin and albumin (n = 27)
Further details: terlipressin (Glypressin; Ferring AB, Malmo, Sweden) was administered initially at a
dose of 3 mg/24 hours by continuous intravenous infusion. Response to treatment was evaluated every
48 hours. If serum creatinine decreased by < 25% of the pretreatment value, the dose of terlipressin
was progressively increased to 12 mg/24 hours. Albumin (Albumina 20%; Kedrion S.p.A., Barga, Italy)
was administered intravenously, 1 g/kg at day 1 and 20-40 g/day subsequently for the duration of the
study.
Group 2: midodrine, octreotide and albumin (n = 21)
Further details: midodrine (Gutron; Lusofarmaco, Peschiera Borromeo, Italy) was administered orally
at a starting dose of 7.5 mg every 8 hours along with octreotide (Longastatina; Italfarmaco S.p.A., Mi-
lan, Italy) administered subcutaneously at a starting dose of 100 μg every 8 hours. If serum creatinine
decreased by < 25% of the pretreatment value, the dose of midodrine was progressively increased to
a maximum of 12.5 mg every 8 hours and octreotide to 200 μg every 8 hours. Albumin (Albumina 20%;
Kedrion S.p.A., Barga, Italy) was administered intravenously, 1 g/kg at day 1 and 20-40 g/day subse-
quently for the duration of the study.
Outcomes The outcomes reported were:
• Mortality
• Adverse events
• Recovery from hepatorenal syndrome
Notes Reasons for post-randomisation dropouts: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were randomized at each hospital using sealed opaque en-
velopes containing the treatment assignments based on random numbers
generated by the Stata statistical package".
Allocation concealment
(selection bias)
Low risk Quote: "Patients were randomized at each hospital using sealed opaque en-
velopes containing the treatment assignments based on random numbers
generated by the Stata statistical package".
Cavallin 2015  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: This information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Comment: One patient was excluded on the basis of undergoing liver trans-
plantation on day 2: this was highly likely to be related to the outcomes.
Selective reporting (re-
porting bias)
Low risk Comment: Study protocol was not available, but the authors have reported
the expected clinical outcomes adequately.
Other bias Low risk Comment: No other bias noted
Cavallin 2015  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: Romania
Number randomised: 25
Post-randomisation dropouts: not stated
Revised sample size: 25
Average age: not stated
Females: not stated
Hepatorenal syndrome type 1: not stated
Hepatorenal syndrome type 2: not stated
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
Follow-up in months: 0.23
Years of recruitment: not stated
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: not stated
Patients with hepatorenal syndrome type II: not stated
Alcoholic cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
Other causes for cirrhosis: not stated
Other important exclusion criteria
• None stated
Interventions Participants were randomly assigned to two groups.
Group 1: Captopril and octreotide (n = 13)
Chelarescu 2003 
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Further details: Octreotide 100 μg intravenously at '8h/d, 7d'.
Group 2: Octreotide (n = 12)
Further details: Octreotide same dose and captopril 6.25 mg twice daily for 7 days
Outcomes The outcomes reported were:
• Mortality
Notes Reasons for post-randomisation dropouts: not stated.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: This information was not available.
Allocation concealment
(selection bias)
Unclear risk Comment: This information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: "double-blind manner"
Comment: Also stated double-blind; there was no mention of a placebo.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "double-blind manner"
Comment: Also stated double-blind; there was no mention of a placebo.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: This information was not available.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Chelarescu 2003  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: Romania
Number randomised: 40
Post-randomisation dropouts: not stated
Revised sample size: 40
Average age: not stated
Females: not stated
Hepatorenal syndrome type 1: 36 (90%)
Hepatorenal syndrome type 2: 4 (10%)
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
Follow-up in months: 1
Years of recruitment: not stated
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Copaci 2013 
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Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: yes
Alcoholic cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
Other causes for cirrhosis: not stated
Other important exclusion criteria
• None stated
Interventions Participants were randomly assigned to two groups.
Group 1: terlipressin and albumin (n = 20)
Further details: patients received terlipressin by continuous intravenous infusion at initial dose of 4
mg/24 hrs, which in case of non-response was progressively increased to 12 mg/24hrs. Patients in both
groups received albumin 1 g/kg body weight on first day, followed by 20–40 g/day.
Group 2: octreotide and albumin (n = 20)
Further details: patients received octreotide at initial dose of 100 µg subcutaneously three times dai-
ly, which in case of non-response was increased to 200 µg three times daily. Patients in both groups re-
ceived albumin 1 g/kg body weight on first day, followed by 20–40 g/day.
Outcomes The outcomes reported were:
• Mortality
• Recovery from hepatorenal syndrome
Notes Reasons for post-randomisation dropouts: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: This information was not available.
Allocation concealment
(selection bias)
Unclear risk Comment: This information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: This information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: This information was not available.
Copaci 2013  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Copaci 2013  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: United States
Number randomised: 28
Post-randomisation dropouts: 2
Revised sample size: 26
Average age: not stated
Females: 5 randomised, unclear after dropouts
Hepatorenal syndrome type 1: not stated
Hepatorenal syndrome type 2: not stated
Alcohol-related cirrhosis: 28
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
Follow-up in months: 0.5
Years of recruitment: not stated
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: not stated
Patients with hepatorenal syndrome type II: not stated
Alcoholic cirrhosis: yes
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
Other causes for cirrhosis: not stated
Other important exclusion criteria
• Other cause of acute renal failure
Interventions Participants were randomly assigned to two groups.
Group 1: surgical (n = 11)
Further details: peritoneovenous shunt within 2 days of randomisation
Group 2: medical (n = 15)
Further details: control, unclear what standard treatment involved, trial from 1978-1983
Outcomes The outcomes reported were:
• Mortality
Notes Reasons for post-randomisation dropouts: refused treatment, developed variceal bleed
Risk of bias
Daskalopoulos 1985 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: This information was not available.
Allocation concealment
(selection bias)
Unclear risk Comment: This information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: This information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Comment: One patient was excluded on the basis of variceal bleeding on the
day of planned surgery: this was highly likely to be related to the treatment
and outcomes.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Daskalopoulos 1985  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: India
Number randomised: 58
Post-randomisation dropouts: 12 (20.7%)
Revised sample size: 46
Average age: 47 years
Females: 10 (21.7%)
Hepatorenal syndrome type 1: 0 (0%)
Hepatorenal syndrome type 2: 46 (100%)
Alcohol-related cirrhosis: 31 (67.4%)
Viral-related cirrhosis: 8 (17.4%)
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): 2 (4.3%)
Other causes for cirrhosis: 5 (10.9%)
Follow-up in months: 3
Years of recruitment: 2009-2011
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: no
Patients with hepatorenal syndrome type II: yes
Alcoholic cirrhosis: yes
Viral-related cirrhosis: yes
Autoimmune disease-related cirrhosis: yes
Ghosh 2013 
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Other causes for cirrhosis: yes
Other important exclusion criteria
• Shock
• Fluid losses
• Treatment with nephrotoxic drugs
• Improvement in renal function following diuretic withdrawal and plasma volume expansion
• Ultrasound evidence of renal parenchymal disease
• Obstructive uropathy and absence of proteinuria more than 500 mg/24 hours
• History of coronary artery disease
• History of cardiomyopathy
• History of ventricular arrhythmia
• History of obstructive arterial disease of the limbs
Interventions Participants were randomly assigned to two groups.
Group 1: noradrenaline and albumin (n = 23)
Further details: continuous infusion of noradrenaline at an initial dose of 0.5 mg/h, designed to achieve
an increase in mean arterial pressure of at least 10 mmHg or an increase in 4 h urine output to more
than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 h in
steps of 0.5 mg/h, up to the maximum dose of 3 mg/h. 20 g albumin/day administered. Albumin was
withheld if central venous pressure was more than 18 cm of saline.
Group 2: terlipressin and albumin (n = 23)
Further details: terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in
serum creatinine level was not observed during the 3-day period, the dose of terlipressin was increased
in a stepwise fashion every 3 days to a maximum of 2 mg every 6 h. 20 g albumin/day administered, al-
bumin was withheld if central venous pressure was more than 18 cm of saline.
Unclear which group post-randomisation dropouts were in
Outcomes The outcomes reported were:
• Mortality
• Adverse events
• Recovery from hepatorenal syndrome
Notes Reasons for post-randomisation dropouts: severe coronary artery disease in 1, sepsis in 7, hepatocellu-
lar carcinoma in 1, diabetic nephropathy in 1 and refusal to participate in 2 patients
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a computer made the randomization code…".
Allocation concealment
(selection bias)
Unclear risk Quote: "with 46 envelopes with half of..".
Comment: Further details of how the allocation was concealed were not re-
ported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "Patients and investigators were not blinded to the treatment assign-
ments".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "Patients and investigators were not blinded to the treatment assign-
ments".
Ghosh 2013  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: abstracts presented information on 60 patients while full article
presented data only on 46. It was not clear from the full text whether the exclu-
sions were after randomisation. If they were, the outcomes were related to the
dropouts.
Selective reporting (re-
porting bias)
Unclear risk Comment: study protocol was not available, but the authors have reported the
expected clinical outcomes adequately.
Other bias Low risk Comment: No other bias noted
Ghosh 2013  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: India
Number randomised: 32
Post-randomisation dropouts: not stated
Revised sample size: 32
Average age: 54 years
Females: 2 (6.3%)
Hepatorenal syndrome type 1: 10 (31.3%)
Hepatorenal syndrome type 2: 22 (68.8%)
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
Follow-up in months: 0.5
Years of recruitment: not stated
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: yes
Alcoholic cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
Other causes for cirrhosis: not stated
Other important exclusion criteria
• None stated
Interventions Participants were randomly assigned to two groups.
Group 1: noradrenaline and albumin (n = 16)
Further details: noradrenaline (0.5-3 mg/h) plus furosemide, along with intravenous albumin
Group 2: terlipressin and albumin (n = 16)
Further details: terlipressin (1-2 mg/4h) along with intravenous albumin
Outcomes The outcomes reported were:
• Recovery from hepatorenal syndrome
Goyal 2008 
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Notes Reasons for post-randomisation dropouts: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: This information was not available.
Allocation concealment
(selection bias)
Unclear risk Comment: This information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "unblinded study"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "unblinded study"
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: This information was not available.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Goyal 2008  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: India
Number randomised: 41
Post-randomisation dropouts: 0 (0%)
Revised sample size: 41
Average age: 56 years
Females: 4 (9.8%)
Hepatorenal syndrome type 1: 41 (100%)
Hepatorenal syndrome type 2: 0 (0%)
Alcohol-related cirrhosis: 28 (68.3%)
Viral-related cirrhosis: 7 (17.1%)
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): not stated
Other causes for cirrhosis: 7 (17.1%)
Follow-up in months: 0.5
Years of recruitment: not stated
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: no
Goyal 2016 
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Alcoholic cirrhosis: yes
Viral-related cirrhosis: yes
Autoimmune disease-related cirrhosis: not stated
Other causes for cirrhosis: yes
Other important exclusion criteria
• Improvement in renal function after central blood volume expansion
• Presence of severe sepsis
• Presence of pancreatitis
• Presence of shock
• Use of nephrotoxic drugs
• History of coronary artery disease
• History of obstructive cardiomyopathy
• History of ventricular arrhythmia
• History of obliterative arterial disease of the limbs
Interventions Participants were randomly assigned to two groups.
Group 1: noradrenaline and albumin (n = 21)
Further details: continuous infusion of noradrenaline (Adrenor, Samarth Life Sciences, Mumbai, In-
dia) at an initial dose of 0.5 mg/h administered by an automatic syringe pump, aimed to achieve an
increase in mean arterial pressure of at least 10 mmHg or an increase in 1 h urine output to > 40 mL.
If either of these goals was not achieved, the noradrenaline dose was stepped up by 0.5 mg/h every
4 h, up to the maximum dose of 3 mg/h. Furosemide was added as intravenous infusion at a dose
of 0.001 mg/kg/min if adequate urine output was not achieved despite an increase in mean arterial
pressure. Furosemide dose was adjusted to maintain a urine output of at least 40 mL/1hr. Patients re-
ceived daily IV albumin (Buminate, Baxter private limited, Gurgaon, India) 20 g/day until the end of the
study period. Albumin administration was stopped temporarily if central venous pressure increased
above 12 cm of saline or if serum albumin was > 4 g/L. All patients received intravenous third-gener-
ation cephalosporins prophylactically during the study period. All patients had an indwelling urinary
catheter for accurate measurement of urine output, which was removed when the patient recovered.
Group 2: terlipressin and albumin (n = 20)
Further details: terlipressin (Remestyp, Ferring Pharmaceuticals , Saint Prex, Switzerland) at an initial
dose of 0.5 mg every 6 hour IV. If a significant (> 25%) reduction in serum creatinine level was not ob-
served at 3 days, the dose of terlipressin was stepped up to 1 mg every 6 hours, up to a maximum of 2
mg every 6 hours. Patients received daily IV albumin (Buminate, Baxter private limited, Gurgaon, India)
20 g/day until the end of the study period. Albumin administration was stopped temporarily if central
venous pressure increased above 12 cm of saline or if serum albumin was > 4 g/L. All patients received
intravenous third-generation cephalosporins prophylactically during the study period. All patients had
an indwelling urinary catheter for accurate measurement of urine output, which was removed when
the patient recovered.
Outcomes The outcomes reported were:
• Mortality
• Adverse events
• Recovery from hepatorenal syndrome
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were randomized into two groups (A and B) using a comput-
er-generated randomization table to receive treatment for 2 weeks".
Goyal 2016  (Continued)
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Allocation concealment
(selection bias)
Unclear risk Comment: This information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "open-label"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "open-label"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
Low risk Comment: study protocol was not available, but the authors have reported the
expected clinical outcomes adequately.
Other bias Low risk Comment: No other bias noted
Goyal 2016  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: India
Number randomised: 60
Post-randomisation dropouts: 0 (0%)
Revised sample size: 60
Average age: not stated
Females: not stated
Hepatorenal syndrome type 1: 60 (100%)
Hepatorenal syndrome type 2: 0 (0%)
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
Follow-up in months: 3
Years of recruitment: not stated
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: no
Alcoholic cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
Other causes for cirrhosis: not stated
Other important exclusion criteria
Indrabi 2013 
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• None stated
Interventions Participants were randomly assigned to two groups.
Group 1: noradrenaline and albumin (n = 30)
Further details: none reported
Group 2: terlipressin and albumin (n = 30)
Further details: none reported
Outcomes The outcomes reported were:
• Mortality
• Recovery from hepatorenal syndrome
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: This information was not available.
Allocation concealment
(selection bias)
Unclear risk Comment: This information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: This information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Indrabi 2013  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 25
Post-randomisation dropouts: not stated
Revised sample size: 25
Average age: not stated
Females: 9 (36%)
Hepatorenal syndrome type 1: not stated
Hepatorenal syndrome type 2: not stated
Alcohol-related cirrhosis: 22 (88%)
Koch 2016 
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Viral-related cirrhosis: 2 (8%)
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): 1 (4%)
Other causes for cirrhosis: 0 (0%)
Follow-up in months: 1
Years of recruitment: not stated
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: not stated
Patients with hepatorenal syndrome type II: not stated
Alcoholic cirrhosis: yes
Viral-related cirrhosis: yes
Autoimmune disease-related cirrhosis: yes
Other causes for cirrhosis: no
Other important exclusion criteria
• None stated
Interventions Participants were randomly assigned to two groups.
Group 1: goal directed therapy (n = 16)
Further details: This protocol was based on three sequential algorithms including global end-diastolic
volume index (GEDVI), extravascular lung water index (EVLWI), cell count in the ascitic fluid and pO2/
FiO2. In summary these algorithms aimed at GEDVI-guided volume expansion within the first 48 h, fol-
lowed by a transpulmonary thermodilation-guided strategy for fluid support using the PiCCO-2-device
(Pulsion Medical Systems SE, Feldkirchen, Germany).
Group 2: no goal directed therapy (n = 9)
Further details: standard care
Outcomes No outcomes of interest for this review were reported.
Notes Reasons for post-randomisation dropouts: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: This information was not available.
Allocation concealment
(selection bias)
Unclear risk Comment: This information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: This information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data
(attrition bias) 
Unclear risk Comment: This information was not available.
Koch 2016  (Continued)
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All outcomes
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Koch 2016  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: Spain
Number randomised: 46
Post-randomisation dropouts: 0 (0%)
Revised sample size: 46
Average age: 57 years
Females: 17 (37%)
Hepatorenal syndrome type 1: 35 (76.1%)
Hepatorenal syndrome type 2: 11 (23.9%)
Alcohol-related cirrhosis: 33 (71.7%)
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
Follow-up in months: 3
Years of recruitment: not stated
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: yes
Alcoholic cirrhosis: yes
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
Other causes for cirrhosis: not stated
Other important exclusion criteria
• Bacterial infection diagnosed by body temperature below 36°C or above 38°C, heart rate above 90
beats/min, respiratory rate above 20 breaths/min and white cell count below 4 or above 12 x 106/L
of above 6% of band forms. N.B. patients could be included if renal failure persisted after infection
resolution.
• Cardiovascular diseases
• Any extrahepatic disease that could affect the short-term prognosis
• Organic nephropathy
• Advanced hepatocellular carcinoma
Interventions Participants were randomly assigned to two groups.
Group 1: terlipressin and albumin (n = 23)
Further details: terlipressin (Glypressin, Ferring AB, Sweden) was administered initially at a dose of 1
mg/4 hour as intravenous (IV) bolus for 3 days. If after the first 3 days serum creatinine had decreased
at least 25% of the pretreatment values, the dose was not modified. In patients in whom serum creati-
nine had not decreased at least 25% of the pretreatment values within the first 3 days, the dose was in-
Martin-Llahi 2008 
Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
63
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
creased to a maximum of 2 mg/4 hour. Terlipressin was given until serum creatinine had decreased be-
low 133 μmol/L or for a maximum of 15 days. Terlipressin administration was withheld if patients de-
veloped signs or symptoms compatible with ischaemic complications. An amendment was made dur-
ing the study to allow treatment with terlipressin in patients assigned to albumin therapy who were po-
tential candidates for liver transplantation if there was no improvement in renal function after 7 days.
Albumin (Albumin 20 percent; Instituto Grífols, Barcelona, Spain) was given at a dose of 1 g/kg during
the first 24 hours, followed by 40 g/day, targeted to obtain a central venous pressure (CVP) between 10
and 15 cm of water. CVP was measured at least once a day throughout the study period. When CVP in-
creased over 15 cm of water, the albumin dose was reduced to 20 g/day and was withheld when CVP in-
creased above 18 cm of water or there were clinical or radiologic signs of pulmonary oedema. In addi-
tion, these patients received IV boluses of furosemide.
Group 2: albumin (n = 23)
Further details: albumin (Albumin 20 percent; Instituto Grífols, Barcelona, Spain) was given at a dose
of 1 g/kg during the first 24 hours, followed by 40 g/day, targeted to obtain a central venous pressure
(CVP) between 10 and 15 cm of water. CVP was measured at least once a day throughout the study peri-
od. When CVP increased over 15 cm of water, the albumin dose was reduced to 20 g/day and was with-
held when CVP increased above 18 cm of water or there were clinical or radiologic signs of pulmonary
oedema. In addition, these patients received IV boluses of furosemide.
Outcomes The outcomes reported were:
• Mortality
• Serious adverse events
• Adverse events
• Recovery from hepatorenal syndrome
• Other features of decompensation
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomization was centralized in the Hospital Clínic of Barcelona and
was done with the use of sealed opaque envelopes containing the treatment
assignments, which were based on random numbers generated by the STATA
statistical package".
Allocation concealment
(selection bias)
Low risk Quote: "Randomization was centralized in the Hospital Clínic of Barcelona and
was done with the use of sealed opaque envelopes containing the treatment
assignments, which were based on random numbers generated by the STATA
statistical package".
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "Second, ideally, the study should have been performed using a dou-
ble-blind design. However, this was not possible because our study was not…".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "Second, ideally, the study should have been performed using a dou-
ble-blind design. However, this was not possible because our study was not…".
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
Low risk Comment: study protocol was not available, but authors have reported the ex-
pected clinical outcomes adequately.
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Other bias Low risk Comment: No other bias noted
Martin-Llahi 2008  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 13
Post-randomisation dropouts: not stated
Revised sample size: 13
Average age: 47 years
Females: 8 (61.5%)
Hepatorenal syndrome type 1: 13 (100%)
Hepatorenal syndrome type 2: 0 (0%)
Alcohol-related cirrhosis: 7 (53.8%)
Viral-related cirrhosis: 4 (30.8%)
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): 1 (7.7%)
Other causes for cirrhosis: 1 (7.7%)
Follow-up in months: 1
Years of recruitment: not stated
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: no
Alcoholic cirrhosis: yes
Viral-related cirrhosis: yes
Autoimmune disease-related cirrhosis: yes
Other causes for cirrhosis: yes
Other important exclusion criteria
• Fulminant hepatic failure
• Sepsis unresponsive to antibiotic treatment
• Severe acute haemorrhages
• Malignancies
• Obstructive/chronic renal failure
• Pregnancy
• Severe cardiopulmonary disease
Interventions Participants were randomly assigned to two groups.
Group 1: MARS (n = 8)
Further details: patients underwent MARS treatment for 6 to 8 hours per treatment day in addition to
standard medical treatment, including haemodiafiltration (HDF), when indicated (need for water re-
moval, severe azotaemia, clinical signs of uremia). The maximum number of MARS treatments allowed
per patient was 10. It was performed daily. A maximum of 2 treatment pauses of 1 d/wk was allowed
to perform HDF or other diagnostic or therapeutic measures. No MARS treatment was performed when
no spontaneous increase in total bilirubin level was observed between the value at the end of 1 single
treatment and the next morning value or if the haemodynamic situation of the patient did not permit
the initiation or maintenance of extracorporeal circulation.
Group 2: haemofiltration (n = 5)
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Further details: The patients underwent standard treatment plus HDF using bicarbonate-buHered
dialysate, performed intermittently for 6 to 8 hours per session. The same type and size dialysis mem-
brane as in the MARS treatment was used for HDF (P5S; Gambro, Hechingen, Germany). Heparin was
administered as the anticoagulant. The indication for HDF was the need for water removal, severe azo-
taemia, and/or presence of uraemic symptoms.
Outcomes The outcomes reported were:
• Mortality
Notes Reasons for post-randomisation dropouts: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "computerized random-number generating program".
Allocation concealment
(selection bias)
Low risk Quote: "sealed envelopes….randomization was performed by pulling the en-
velope with lowest number in the sequence..".
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: This information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: This information was not available.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Mitzner 2000  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 52
Post-randomisation dropouts: 0 (0%)
Revised sample size: 52
Average age: 60 years
Females: 31 (59.6%)
Hepatorenal syndrome type 1: 52 (100%)
Hepatorenal syndrome type 2: 0 (0%)
Alcohol-related cirrhosis: 7 (13.5%)
Viral-related cirrhosis: 45 (86.5%)
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): 0 (0%)
Other causes for cirrhosis: 0 (0%)
Follow-up in months: 3
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Years of recruitment: 2002-2005
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: no
Alcoholic cirrhosis: yes
Viral-related cirrhosis: yes
Autoimmune disease-related cirrhosis: no
Other causes for cirrhosis: no
Other important exclusion criteria
• Heart failure
• Respiratory failure
• Arterial hypertension
• Coronary artery disease
• Peripheral artery disease
• Age > 75 years
• Hepatocellular carcinoma
Interventions Participants were randomly assigned to two groups.
Group 1: terlipressin and albumin (n = 26)
Further details: intravenous boluses of terlipressin (Glipressin 0.5 mg; Laboratoires Ferring SpA, Milano,
Italy) at the dose of 1 mg/8h/5days followed by 0.5 mg/8h for two weeks plus albumin (described in al-
bumin group). In patients developing recurrence of hepatorenal syndrome, terlipressin and albumin
were administered again following the same schedule of the initial treatment. 
Group 2: albumin (n = 26)
Further details: intravenous boluses of albumin alone (Albumina Grifols 20%, 20 g of Albumin/100 mL;
Barcelona, Spain). Albumin was given at a weight-based dosage (1 g/kg body weight during the first day
and 20–40 g/day thereafter).
Outcomes The outcomes reported were:
• Mortality
• Recovery from hepatorenal syndrome
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "For inclusion, randomization divided eligible subjects at study start in-
to group A and B individually and sequentially, in a 1:1 ratio from a computer
generated list ".
Allocation concealment
(selection bias)
Low risk Quote: "For inclusion, randomization divided eligible subjects at study start in-
to group A and B individually and sequentially, in a 1:1 ratio from a computer
generated list ".
Blinding of participants
and personnel (perfor-
mance bias) 
Unclear risk Comment: This information was not available.
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Neri 2008  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: India
Number randomised: 60
Post-randomisation dropouts: 0 (0%)
Revised sample size: 60
Average age: 53 years
Females: not stated
Hepatorenal syndrome type 1: 60 (100%)
Hepatorenal syndrome type 2: 0 (0%)
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
Follow-up in months: 3
Years of recruitment: not stated
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: no
Alcoholic cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
Other causes for cirrhosis: not stated
Other important exclusion criteria
• Improvement in renal function after plasma volume expansion
• Evidence of sepsis excluding spontaneous bacterial peritonitis
• Coronary artery disease
• Obstructive cardiomyopathy
• Ventricular arrhythmia
• Obliterative arterial disease
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Interventions Participants were randomly assigned to two groups.
Group 1: noradrenaline and albumin (n = 30)
Further details: either continuous infusion of noradrenaline at an initial dose of 0.5 mg/h, designed to
achieve an increase in mean arterial pressure of at least 10 mmHg, or an increase in 4-h urine output to
more than 200 mL. When one of these goals was not achieved, the noradrenaline dose was increased
every 4 h in steps of 0.5 mg/h, up to the maximum dose of 3 mg/h.
Group 2: terlipressin and albumin (n = 30)
Further details: terlipressin as an IV bolus of 0.5 mg every 6 h; if a significant reduction in serum cre-
atinine level (≥ 1 mg/dL) was not observed during each 3-day period, the dose of terlipressin was in-
creased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 h to maximum of 8 mg per
day.
Outcomes The outcomes reported were:
• Mortality
• Recovery from hepatorenal syndrome
• Costs
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "computer generated randomization ".
Allocation concealment
(selection bias)
Unclear risk Comment: This information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: This information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Saif 2018  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: multicentre - 30 US, 2 Germany, 3 Russia
Number randomised: 112
Post-randomisation dropouts: 0 (0%)
Revised sample size: 112
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Average age: 52 years
Females: 32 (28.6%)
Hepatorenal syndrome type 1: 112 (100%)
Hepatorenal syndrome type 2: 0 (0%)
Alcohol-related cirrhosis: 40 (35.7%)
Viral-related cirrhosis: 46 (41.1%)
Autoimmune disease-related cirrhosis (example, PSC, PBC, AIH): 3 (2.7%)
Other causes for cirrhosis: 17 (15.2%)
Follow-up in months: 6
Years of recruitment: not stated
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: no
Alcoholic cirrhosis: yes
Viral-related cirrhosis: yes
Autoimmune disease-related cirrhosis: yes
Other causes for cirrhosis: yes
Other important exclusion criteria
• Evidence of obstructive or parenchymal renal disease (e.g. acute tubular necrosis, glomerular dis-
eases, interstitial nephritis, and urinary obstruction)
• Use of nephrotoxic drugs
• Shock
• Uncontrolled bacterial infection
• Uncorrected fluid losses
• Acute liver disease because of factors known to also be nephrotoxic
• Severe cardiovascular disease as determined by the clinical judgement of individual investigators
Interventions Participants were randomly assigned to two groups.
Group 1: terlipressin and albumin (n = 56)
Further details: terlipressin at a dose of 1 mg administered by slow intravenous (IV) push every 6 hours,
patients receive concomitant IV albumin (100 g on day 1 and 25 g daily until end of treatment) as per
standard medical practice. If after 3 days of therapy, serum creatinine level had not decreased by at
least 30% from the baseline value, the dose of terlipressin was increased to 2 mg every 6 hours. Pa-
tients could receive study drug for a maximum of 14 days but were to be discontinued from the study
earlier for treatment failure or liver transplantation. Patients could also be withdrawn for an adverse
event, withdrawal of consent, or physician decision/administrative reason. Patients who achieved
treatment success could be discontinued or continue on therapy at the investigator’s discretion un-
til the maximum of 14 days. If judged by the investigator to be potentially beneficial, patients who
demonstrated at least a partial response during the initial 14-day treatment course and then developed
recurrence of hepatorenal syndrome type 1 during the follow-up period were eligible to be retreated
with the initially assigned study drug for up to an additional 14 days.
Group 2: albumin (n = 56)
Further details: patients receive concomitant IV albumin (100 g on day 1 and 25 g daily until end of
treatment) as per standard medical practice. If after 3 days of therapy, serum creatinine level had not
decreased by at least 30% from the baseline value, the dose of the placebo was increased to 2 mg every
6 hours. Patients could receive placebo for a maximum of 14 days but were to be discontinued from
the study earlier for treatment failure or liver transplantation. Patients could also be withdrawn for
an adverse event, withdrawal of consent, or physician decision/administrative reason. Patients who
achieved treatment success could be discontinued or continue on therapy at the investigator’s discre-
tion until the maximum of 14 days. If judged by the investigator to be potentially beneficial, patients
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who demonstrated at least a partial response during the initial 14-day treatment course and then de-
veloped recurrence of hepatorenal syndrome type 1 during the follow-up period were eligible to be re-
treated with the initially assigned study drug for up to an additional 14 days..
Outcomes The outcomes reported were:
• Mortality
• Serious adverse events
• Adverse events
• Liver transplantation
• Recovery from hepatorenal syndrome
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "subjects were randomized through an interactive voice response sys-
tem and computer-generated randomization scheme".
Allocation concealment
(selection bias)
Low risk Quote: "subjects were randomized through an interactive voice response sys-
tem and computer-generated randomization scheme".
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Double-Blind, Placebo-Controlled"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Double-Blind, Placebo-Controlled"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
Low risk Comment: Study protocol was not available, but authors have reported the ex-
pected clinical outcomes adequately.
Other bias Low risk Comment: No other bias noted
Sanyal 2008  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: India
Number randomised: 40
Post-randomisation dropouts: 0 (0%)
Revised sample size: 40
Average age: 48 years
Females: 6 (15%)
Hepatorenal syndrome type 1: 40 (100%)
Hepatorenal syndrome type 2: 0 (0%)
Alcohol-related cirrhosis: 26 (65%)
Viral-related cirrhosis: 9 (22.5%)
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Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): 1 (2.5%)
Other causes for cirrhosis: 4 (10%)
Follow-up in months: 0.5
Years of recruitment: 2005-2006
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: no
Alcoholic cirrhosis: yes
Viral-related cirrhosis: yes
Autoimmune disease-related cirrhosis: yes
Other causes for cirrhosis: yes
Other important exclusion criteria
• Improvement in renal function after central blood volume expansion
• History of infection within the past week, excluding spontaneous bacterial peritonitis
• History of coronary artery disease
• History of obstructive cardiomyopathy
• History of ventricular arrhythmia
• History of obliterative arterial disease of the limbs
Interventions Participants were randomly assigned to two groups.
Group 1: noradrenaline and albumin (n = 20)
Further details: patients received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/
h, designed to achieve an increase in mean arterial pressure of at least 10 mmHg or an increase in 4 h
urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose
was increased every 4 h in steps of 0.5 mg/h, up to the maximum dose of 3 mg/h. The patients from
both groups received daily IV albumin 20–40 g/day until the end of the study period. Albumin admin-
istration was transiently stopped if central venous pressure increased above 18 cm of saline. Diuret-
ics were not given during the treatment period. All patients received third-generation cephalosporins
prophylactically during the study period. All patients had an indwelling urinary catheter until recovery
from the hepatorenal syndrome for better measurement of urine output. It was removed when the pa-
tient recovered.
Group 2: terlipressin and albumin (n = 20)
Further details: patients received terlipressin as an IV bolus of 0.5 mg every 6 h. If a significant reduc-
tion in serum creatinine level (≥ 1 mg/dL) was not observed during each 3-day period, the dose of
terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 h. The
patients from both groups received daily IV albumin 20–40 g/day until the end of the study period.
Albumin administration was transiently stopped if central venous pressure increased above 18 cm
of saline. Diuretics were not given during the treatment period. All patients received third-genera-
tion cephalosporins prophylactically during the study period. All patients had an indwelling urinary
catheter until recovery from the hepatorenal syndrome for better measurement of urine output. It was
removed when the patient recovered.
Outcomes The outcomes reported were:
• Mortality
• Adverse events
• Recovery from hepatorenal syndrome
• Costs
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Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were randomized into two groups by a computer-generated
randomization chart".
Allocation concealment
(selection bias)
Unclear risk Comment: This information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "open-label"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "open-label"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Sharma 2008  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: India
Number randomised: 60
Post-randomisation dropouts: 14 (23.3%)
Revised sample size: 46
Average age: 49 years
Females: 8 (17.4%)
Hepatorenal syndrome type 1: 46 (100%)
Hepatorenal syndrome type 2: 0 (0%)
Alcohol-related cirrhosis: 22 (47.8%)
Viral-related cirrhosis: 15 (32.6%)
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): 3 (6.5%)
Other causes for cirrhosis: 6 (13%)
Follow-up in months: 1
Years of recruitment: 2009-2011
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: no
Singh 2012 
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Alcoholic cirrhosis: yes
Viral-related cirrhosis: yes
Autoimmune disease-related cirrhosis: yes
Other causes for cirrhosis: yes
Other important exclusion criteria
• History of coronary artery disease
• History of cardiomyopathy
• History of ventricular arrhythmia
• History of obstructive arterial disease of the limbs
Interventions Participants were randomly assigned to two groups.
Group 1: noradrenaline and albumin (n = 23)
Further details: patients received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a signif-
icant reduction in serum creatinine level was not observed during a 3-day period, the dose of terli-
pressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 h. Patients in ei-
ther group received treatment with terlipressin or noradrenaline with 20 g albumin/day. Albumin was
withheld if central venous pressure was more than 18 cm of saline.
Group 2: terlipressin and albumin (n = 23)
Further details: patients received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/
h, designed to achieve an increase in mean arterial pressure of at least 10 mmHg or an increase in 4 h
urine output of more than 200 mL. When one of these goals was not achieved, the noradrenaline dose
was increased every 4 h in steps of 0.5 mg/h, up to the maximum dose of 3 mg/h. Patients in either
group received treatment with terlipressin or noradrenaline with 20 g albumin/day. Albumin was with-
held if central venous pressure was more than 18 cm of saline.
Outcomes The outcomes reported were:
• Mortality
• Adverse events
• Recovery from hepatorenal syndrome
• Costs
Notes Reasons for post-randomisation dropouts: severe coronary artery disease in three, sepsis in nine, hepa-
tocellular carcinoma in one and diabetic nephropathy in one patient.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "A computer made the randomization code with 46 envelopes".
Allocation concealment
(selection bias)
Unclear risk Quote: "with 46 envelopes, half for terlipressin...".
Comment: Further details of how the allocation was concealed were not re-
ported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "Patients and investigators were not blinded to the treatment assign-
ments".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "Patients and investigators were not blinded to the treatment assign-
ments".
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: abstracts presented information on 60 patients while full article
presented data only on 46. It was not clear from the full text whether the exclu-
sions were after randomisation. If they were, the outcomes were related to the
dropouts.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Singh 2012  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: India
Number randomised: 24
Post-randomisation dropouts: 0 (0%)
Revised sample size: 24
Average age: 52 years
Females: 7 (29.2%)
Hepatorenal syndrome type 1: 24 (100%)
Hepatorenal syndrome type 2: 0 (0%)
Alcohol-related cirrhosis: 8 (33.3%)
Viral-related cirrhosis: 9 (37.5%)
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): 0 (0%)
Other causes for cirrhosis: 7 (29.2%)
Follow-up in months: 0.5
Years of recruitment: not stated
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: no
Alcoholic cirrhosis: yes
Viral-related cirrhosis: yes
Autoimmune disease-related cirrhosis: no
Other causes for cirrhosis: yes
Other important exclusion criteria
• Shock
• Ongoing bacterial infection
• Fluid losses
• Treatment with nephrotoxic drugs
• No improvement in renal function following diuretic withdrawal and plasma volume expansion
• Proteinuria < 500 mg/day
• No ultrasonographic evidence of renal parenchymal disease or urinary tract obstruction
Interventions Participants were randomly assigned to two groups.
Group 1: terlipressin and albumin (n = 12)
Solanki 2003 
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Further details: patients received terlipressin 1 mg IV at 12 h intervals The patients from both groups
received IV albumin infusion, 20 g/day and fresh frozen plasma 150 mL every 8 h, until central venous
pressure reached the upper normal range (10–12 cm of H2O).
Group 2: albumin (n = 12)
Further details: patients received placebo (distilled water) 1 mL IV at 12 h intervals for the study period
(15 days). The patients from both groups received IV albumin infusion, 20 g/day and fresh frozen plas-
ma 150 mL every 8 h, until central venous pressure reached the upper normal range (10–12 cm of H2O).
Outcomes The outcomes reported were:
• Mortality
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "random-number table"
Allocation concealment
(selection bias)
Unclear risk Comment: This information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "single-blind"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "single-blind"
Comment: Further information on whether outcome assessors were blinded
was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Solanki 2003  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: USA
Number randomised: 12
Post-randomisation dropouts: 0 (0%)
Revised sample size: 12
Average age: 59 years
Females: 5 (41.7%)
Hepatorenal syndrome type 1: 12
Hepatorenal syndrome type 2: 0
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): not stated
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Other causes for cirrhosis: not stated
Follow-up in months: 6
Years of recruitment: 2014-2016
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: not stated
Patients with hepatorenal syndrome type II: not stated
Alcoholic cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
Other causes for cirrhosis: not stated
Other important exclusion criteria
• Patients with labelled contraindications to pentoxifylline (allergy or hypersensitivity to pentoxifylline
or intolerance to methylxanthines (e.g. caffeine, theophylline))
• Recent cerebral or retinal haemorrhage
• Recent pregnancy
• Concurrent use of nephrotoxic drugs
• Uncontrolled bacterial infection
• Renal parenchymal disease (e.g. acute tubular necrosis, glomerular disease, interstitial nephritis, uri-
nary obstruction)
• Shock
• TNFα antagonist use
• Severe or poorly controlled comorbid disease as determined by the principal investigator to hinder
the ability of the subject to adhere to study protocols
Interventions Participants were randomly assigned to two groups.
Group 1: midodrine, octreotide, pentoxifylline and albumin (n = 6)
Further details: 14-day course of pentoxifylline 400 mg three times a day or the equivalent dose adjust-
ed for renal impairment [400 mg twice a day for estimated glomerular filtration rate 10-50 mg/dL and
400 mg once a day for eGFR < 10 mg/ dL]
Group 2: midodrine, octreotide and albumin (n = 6)
Further details: not provided
Outcomes The outcomes reported were:
• Mortality
• Liver transplantation
• Recovery from hepatorenal syndrome
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: This information was not available.
Stine 2018  (Continued)
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Allocation concealment
(selection bias)
Unclear risk Comment: This information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "randomized, placebo-controlled, triple blinded pilot study"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "randomized, placebo-controlled, triple blinded pilot study"
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Stine 2018  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: Iran
Number randomised: 23
Post-randomisation dropouts: 0 (0%)
Revised sample size: 23
Average age: 52 years
Females: 8 (34.8%)
Hepatorenal syndrome type 1: 15 (65.2%)
Hepatorenal syndrome type 2: 8 (34.8%)
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
Follow-up in months: 3
Years of recruitment: 2011-2012
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: yes
Patients with hepatorenal syndrome type II: yes
Alcoholic cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
Other causes for cirrhosis: not stated
Other important exclusion criteria
• Evidence of hepatocellular carcinoma
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• Recent history of related complications of cirrhosis
Interventions Participants were randomly assigned to two groups.
Group 1: noradrenaline and albumin (n = 11)
Further details: patients received a continuous infusion of noradrenaline at an initial dose of 0.1 μg/
kg/min, aimed to attain an increase in mean arterial pressure of at least 10 mmHg. In case of lack of
increase in baseline mean arterial pressure of at least 10 mmHg, noradrenalin was increased every 4
hours in steps of 0.05 μg/kg/min up to the maximum dose of 0.7 μg/kg/min. Noradrenaline was admin-
istered either until hepatorenal syndrome reversal or for a maximum of 15 days. Noradrenaline doses
were subsequently tapered to 0 over 3 days. In addition, an amount of 20 to 60 g/d of albumin was in-
fused in all patients to maintain central venous pressure in the range of 10 to 15 mmHg.
Group 2: midodrine, octreotide and albumin (n = 12)
Further details: octreotide was administered subcutaneously at an initial dose of 100 μg 3 times daily
and then, if necessary, increased to 200 μg 3 times daily. Midodrine was administered orally at an initial
dose of 5 mg 3 times daily, and in case of lack of increase in baseline mean arterial pressure of at least
15 mmHg, midodrine was increased every 24 hours in steps of 5 mg 3 times daily up to the maximum
dose of 15 mg 3 times daily, if needed. In addition, an amount of 20 to 60 g/d of albumin was infused in
all patients to maintain central venous pressure in the range of 10 to 15 mmHg.
Outcomes The outcomes reported were:
• Mortality
• Recovery from hepatorenal syndrome
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: This information was not available.
Allocation concealment
(selection bias)
Unclear risk Comment: This information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: This information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: There were no post-randomisation dropouts.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Tavakkoli 2012  (Continued)
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Methods Randomised clinical trial
Participants Country: China
Number randomised: 15
Post-randomisation dropouts: not stated
Revised sample size: 15
Average age: 48 years
Females: 3 (20%)
Hepatorenal syndrome type 1: not stated
Hepatorenal syndrome type 2: not stated
Alcohol-related cirrhosis: 4 (26.7%)
Viral-related cirrhosis: 13 (86.7%)
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): not stated
Other causes for cirrhosis: 2 (13.3%)
Follow-up in months: 0.2
Years of recruitment: 2000
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: not stated
Patients with hepatorenal syndrome type II: not stated
Alcoholic cirrhosis: yes
Viral-related cirrhosis: yes
Autoimmune disease-related cirrhosis: not stated
Other causes for cirrhosis: yes
Other important exclusion criteria
• Shock
• Persistent bacterial infection before and during treatment
• Use of nephrotoxic drugs
• Urinary tract obstruction
• No renal parenchymal lesions in either kidney
Interventions Participants were randomly assigned to two groups.
Group 1: terlipressin and albumin (n = 8)
Further details: terlipressin given by intravenous infusion once every 12 h for a total of 5 days; control
group: spironolactone 80mg and furosemide 40 mg, 3 times a day, for five days. Infusion of albumin
was not restricted during the observation period of the two groups.
Group 2: albumin (n = 7)
Further details: infusion of albumin was not restricted during the observation period of the two groups.
Outcomes No outcomes of interest for this review were reported.
Notes Reasons for post-randomisation dropouts: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: This information was not available.
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Allocation concealment
(selection bias)
Unclear risk Comment: This information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: This information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: This information was not available.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Yang 2001  (Continued)
 
 
Methods Randomised clinical trial
Participants Country: Pakistan
Number randomised: 50
Post-randomisation dropouts: not stated
Revised sample size: 50
Average age: not stated
Females: not stated
Hepatorenal syndrome type 1: not stated
Hepatorenal syndrome type 2: not stated
Alcohol-related cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis (for example, PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
Follow-up in months: 3
Years of recruitment: not stated
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
Additional treatment for ascites: not stated
Important inclusion and exclusion criteria
Patients with hepatorenal syndrome type I: not stated
Patients with hepatorenal syndrome type II: not stated
Alcoholic cirrhosis: not stated
Viral-related cirrhosis: not stated
Autoimmune disease-related cirrhosis: not stated
Other causes for cirrhosis: not stated
Other important exclusion criteria
• Bacterial infection
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• Cardiovascular diseases
• Organic nephropathy
• Hepatocellular carcinoma
Interventions Participants were randomly assigned to two groups.
Group 1: terlipressin and albumin (n = 25)
Further details: terlipressin (1 mg/4 hourly, IV), and albumin (1 g/kg followed by 20-40 g/day)
Group 2: albumin (n = 25)
Further details: albumin (1 g/kg followed by 20-40 g/day)
Outcomes The outcomes reported were:
• Mortality
Notes Reasons for post-randomisation dropouts: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: This information was not available.
Allocation concealment
(selection bias)
Unclear risk Comment: This information was not available.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: This information was not available.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: Authors mentioned intention-to-treat analysis, but not clear if they
imputed any data.
Selective reporting (re-
porting bias)
Unclear risk Comment: No protocol was available.
Other bias Low risk Comment: No other bias noted
Zafar 2012  (Continued)
AIH: autoimmune hepatitis
CVP: central venous pressure
EVLWI: extravascular lung water index
GEDVI: global end-diastolic volume index
HDF: haemodiafiltration
HRS: hepatorenal syndrome
IV: intravenous
MARS: molecular adsorbent recirculating system
PBC: primary biliary cholangitis
PICCO: pulse contour cardiac output
pO2/FiO2: partial pressure of oxygen/fractional inspired oxygen
PSC: primary sclerosing cholangitis
SNOSE: sequentially numbered opaque sealed envelopes
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Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Abutaleb 2007 Not a randomised controlled trial
Ackerman 2002 Patients did not have hepatorenal syndrome
Angeli 1999 Not a randomised controlled trial
Angeli 2015 Not a randomised controlled trial
Antoniades 2003 Not a randomised controlled trial
Casado Caballero 1996 Not a randomised controlled trial
Clewell 1994 Not a randomised controlled trial
Conn 2000 Not a randomised controlled trial
Duhamel 2000 Not a randomised controlled trial
Durkin 1995 Not a randomised controlled trial
Elia 2015 Not a randomised controlled trial
Gines 2005 Not a randomised controlled trial
Giostra 1995 Not a randomised controlled trial
Hadengue 1998 In this cross-over trial, the duration of treatment was 48 hours and the wash-out period was 24
hours. No meaningful data could be obtained from this study.
KaHy 1999 Not a randomised controlled trial
Kalambokis 2005 Not a randomised controlled trial
Kalambokis 2017 Not a randomised controlled trial
Mullen 2002 Not a randomised controlled trial
Ortega 2002 Not a randomised controlled trial
Pauwels 2008 Not a randomised controlled trial
Pomier-Layrargues 2003 In this cross-over trial, the duration of treatment was 96 hours without any wash-out period. No
meaningful data could be obtained from this study
Robertson 2014 Not a randomised controlled trial
Srivastava 2015 Not a randomised controlled trial
Sugerman 1970 Not a randomised controlled trial
Sugerman 1971 Not a randomised controlled trial
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Study Reason for exclusion
Testro 2009 Not a randomised controlled trial
Valer-Fandó 2004 Unclear if study was a randomised controlled trial and no further information available
Varajic 2017 Variations of different forms of goal-directed therapy
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title A multi-center, randomized, placebo controlled, double-blind study to confirm efficacy and safety
of terlipressin in subjects with hepatorenal syndrome type 1 (the CONFIRM Study)
Methods Randomised controlled trial
Participants Inclusion Criteria:
• Written informed consent by subject or legally authorised representative
• At least 18 years of age
• Cirrhosis and ascites
• Rapidly progressive worsening in renal function to a serum creatinine (SCr) at least 2.25 mg/dL
and meeting a trajectory for SCr to double over 2 weeks
• No sustained improvement in renal function (less than 20% decrease in SCr and SCr at least 2.25
mg/dL) at least 48 hours after diuretic withdrawal and the beginning of plasma volume expansion
with albumin
Exclusion Criteria:
• Serum creatinine level greater than 7.0 mg/dL
• At least 1 event of large volume paracentesis (LVP) at least 4 L within 2 days of randomisation
• Sepsis and/or uncontrolled bacterial infection (e.g. persisting bacteraemia, persisting ascitic fluid
leucocytosis, fever, increasing leucocytosis with vasomotor instability)
• Fewer than 2 days anti-infective therapy for documented or suspected infection
• Shock
• Current or recent (within 4 weeks) treatment with or exposure to nephrotoxic agents: e.g.
aminoglycosides, amphotericin, cyclosporine A, cisplatin, nonsteroidal anti-inflammatory drugs
(NSAIDs: e.g. ibuprofen, naproxen, diclofenac), significant exposure to radiographic contrast
agents (large doses or multiple injections of iodinated contrast media; e.g, during coronary or ab-
dominal angiogram)
• Estimated life expectancy of fewer than 3 days
• Superimposed acute liver injury due to drugs (e.g. acetaminophen), dietary supplements, herbal
preparations, viral hepatitis, or toxins (e.g. Amanita toxin with mushroom poisoning carbon tetra-
chloride), with the exception of acute alcoholic hepatitis
• Proteinuria greater than 500 mg/day
• Evidence of obstructive uropathy or parenchymal renal disease on ultrasound or other imaging
• Tubular epithelial casts, heme granular casts, hematuria or microhematuria (greater than 50 red
blood cells per high power field in the absence of recent catheterisation) on urinalysis
Note: Urine sediment examination is required to exclude presence of heme granular casts and oth-
er clinically significant casts.
• Subjects known to be pregnant; all women of child-bearing age and potential must have a nega-
tive pregnancy test.
• Severe cardiovascular disease, including, but not limited to, unstable angina, pulmonary edema,
congestive heart failure requiring increasing doses of drug therapy, or persisting symptomatic
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peripheral vascular disease, myocardial infarction or stable chronic angina within the past 12
months, or any other cardiovascular disease judged by the investigator to be severe
• Current or recent (within 4 weeks) renal replacement therapy (RRT)
• Participation in other clinical research involving investigational medicinal products within 30
days of randomisation
• Transjugular intrahepatic portosystemic shunt (TIPS) within 30 days of randomisation
• Use of vasopressors (e.g. norepinephrine, epinephrine or vasopressin dopamine or other vaso-
pressors) of at least 3 consecutive days within the prior 14-day screening period. Patients receiv-
ing a vasopressor other than midodrine within 24 hours of qualifying SCr are excluded, i.e. a 24-
h washout is required prior to enrolment.
Note: Patients receiving midodrine and octreotide may be enrolled. Midodrine and octreotide
treatment must be stopped prior to randomisation.
* Known allergy or sensitivity to terlipressin or another component of the study treatment
Interventions Participants are randomly assigned to two groups.
Group 1: terlipressin acetate
Further details: lyophilised terlipressin acetate 1 mg by intravenous bolus injection every 6 hours
Group 2: placebo
Further details: 11 mg mannitol reconstituted with 5 mL of sterile 0.9% sodium chloride solution
Outcomes The outcomes to be reported are:
• Recovery from hepatorenal syndrome
Starting date 12 May 2016
Contact information Lisa Fitzgerald 800-556-3314 clinicaltrials@mnk.com
Notes  
NCT02770716  (Continued)
 
 
Trial name or title Pros & cons of norepinephrine infusion versus midodrine & octreotide in patients with hepatorenal
syndrome type 1 in intensive care unit
Methods Randomised controlled trial
Participants Inclusion Criteria:
• All patients that will be included in the study have cirrhosis as diagnosed by clinical, biochemical,
and ultrasound findings, with HRS type 1, the absence of bacterial infections; however, patients
with bacterial infections could be included in the study if renal failure persisted after infection
resolution by clinical, laboratory indices up to 48 hours.
Exclusion Criteria:
• Patients will be excluded if there are advanced cardiovascular diseases due to poor prognosis or
any extrahepatic disease that could affect the short-term prognosis, the presence of advanced
hepatocellular carcinoma or presence of contraindication to norepinephrine as hypotension due
to blood volume deficits except emergency measure, mesenteric or peripheral vascular thrombo-
sis unless there is life-saving procedure, profound hypoxia, or hypercarbia.
Interventions Participants are randomly assigned to two groups.
Group 1: noradrenaline
NCT03455322 
Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
85
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Further details: intravenous infusion noradrenaline in a dose of 0.05-0.3 μg/Kg/min to keep mean
arterial pressure ≥ 80-100 mmHg and continued either until hepatorenal syndrome reversal or for
maximum 10 days
Group 2: midodrine and octreotide
Further details: oral midodrine 5 mg three times/day and can be increased every 24 h up to 12.5 mg
three times daily plus octreotide 100 μg/ 6h subcutaneous & if needed increased to 200μg/6h
Outcomes The outcomes to be reported are:
• Mortality
• Recovery from hepatorenal syndrome
• Adverse events
• Hospital stay
• Costs
Starting date 8 March 2018
Contact information Eman El-Desoki 01227409501 eman18350@gmail.com
Notes  
NCT03455322  (Continued)
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• Diagnosis of cirrhosis and ascites
• Diagnosis of acute kidney injury (AKI) according to International Club of Ascites AKI criteria (ICA-AKI) criteria*
• No response after two consecutive days of diuretic withdrawal and plasma volume expansion with albumin 1 g per kg of body weight
• Absence of shock
• No current or recent use of nephrotoxic drugs (nonsteroidal anti-inflammatory drugs (NSAIDs), aminoglycosides, iodinated contrast
media, etc.)
• No macroscopic signs of structural kidney injury, defined as: absence of proteinuria (> 500 mg/day), absence of microhaematuria (>
50 red blood cells per high-power field), and normal findings on renal ultrasonography. Individuals who fulfil these criteria may still
have structural damage such as tubular damage. Urine biomarkers will become an important element in making a more accurate
differential diagnosis between hepatorenal syndrome and acute tubular necrosis.
Table 1.   Criteria for diagnosis of hepatorenal syndrome  (Continued)
*Increase in serum creatinine ≥ 0.3 mg/dL (≥ 26.5 µmol/L) within 48 hours or ≥ 50% increase in serum creatinine from baseline which is
known or presumed to have occurred within the previous seven days.
Source: Angeli 2015a
AKI: acute kidney injury
ICA: international club of ascites
NSAIDs: nonsteroidal anti-inflammatory drugs
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Study name Intervention 1 Intervention 2 In-
ter-
ven-
tion
1:
num-
ber
of
par-
tic-
i-
pants
In-
ter-
ven-
tion
2:
num-
ber
of
par-
tic-
i-
pants
He-
pa-
tore-
nal
syn-
drome
type
1
He-
pa-
tore-
nal
syn-
drome
type
2
Alco-
hol-re-
lated
cir-
rho-
sis:
num-
ber
of
par-
tici-
pants
Vi-
ral-re-
lated
cir-
rho-
sis:
num-
ber
of
par-
tici-
pants
Autoim-
mune
dis-
ease-re-
lated
cirrho-
sis (ex-
ample,
PSC,
PBC,
AIH):
num-
ber of
partici-
pants
Other
causes
for cir-
rhosis:
num-
ber of
partic-
ipants
Addi-
tional
treat-
ment for
ascites
Years of
randomi-
sation
Av-
er-
age
fol-
low-up
in
months
Risk
of
bias
Alessandria
2007
Albumin plus terlipressin Albumin plus noradrena-
line
12 10 9 13 6 Not
stat-
ed
Not stat-
ed
Not
stated
Yes Not stated 1 High
Arora 2018 Albumin plus terlipressin Albumin plus noradrena-
line
60 60 120 0 87 18 5 10 Not stat-
ed
2015-2016 1 High
Badawy
2013
Albumin plus terlipressin Albumin plus noradrena-
line
26 25 51 0 5 47 7 11 No 2009-2012 0.5 High
Ghosh 2013 Albumin plus terlipressin Albumin plus noradrena-
line
23 23 0 46 31 8 2 5 Yes 2009-2011 3 High
Goyal 2008 Albumin plus terlipressin Albumin plus noradrena-
line
16 16 10 22 Not
stat-
ed
Not
stat-
ed
Not stat-
ed
Not
stated
Not stat-
ed
Not stated 0.5 High
Goyal 2016 Albumin plus terlipressin Albumin plus noradrena-
line
20 21 41 0 28 7 Not stat-
ed
7 Not stat-
ed
Not stated 0.5 High
Indrabi 2013 Albumin plus terlipressin Albumin plus noradrena-
line
30 30 60 0 Not
stat-
ed
Not
stat-
ed
Not stat-
ed
Not
stated
Not stat-
ed
Not stated 3 High
Saif 2018 Albumin plus terlipressin Albumin plus noradrena-
line
30 30 60 0 Not
stat-
ed
Not
stat-
ed
Not stat-
ed
Not
stated
Not stat-
ed
Not stated 3 High
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Sharma
2008
Albumin plus terlipressin Albumin plus noradrena-
line
20 20 40 0 26 9 1 4 Yes 2005-2006 0.5 High
Singh 2012 Albumin plus terlipressin Albumin plus noradrena-
line
23 23 46 0 22 15 3 6 Not stat-
ed
2009-2011 1 High
Boyer 2016 Albumin plus terlipressin Albumin 97 99 196 0 103 95 9 55 Not stat-
ed
2010-2013 3 High
Martin-Llahi
2008
Albumin plus terlipressin Albumin 23 23 35 11 33 Not
stat-
ed
Not stat-
ed
Not
stated
Not stat-
ed
Not stated 3 High
Neri 2008 Albumin plus terlipressin Albumin 26 26 52 0 7 45 0 0 Not stat-
ed
2002-2005 3 High
Sanyal 2008 Albumin plus terlipressin Albumin 56 56 112 0 40 46 3 17 Not stat-
ed
Not stated 6 Low
Solanki
2003
Albumin plus terlipressin Albumin 12 12 24 0 8 9 0 7 Yes Not stated 0.5 High
Yang 2001 Albumin plus terlipressin Albumin 8 7 Not
stat-
ed
Not
stat-
ed
4 13 Not stat-
ed
Not
stated
Not stat-
ed
2000 0.2 High
Zafar 2012 Albumin plus terlipressin Albumin 25 25 Not
stat-
ed*
Not
stat-
ed*
Not
stat-
ed
Not
stat-
ed
Not stat-
ed
Not
stated
Not stat-
ed
Not stated 3 High
Cavallin
2015
Albumin plus terlipressin Albumin plus midodrine
plus octreotide
27 21 44 4 0 18 Not stat-
ed
Not
stated
Not stat-
ed
2008-2012 3 High
Copaci 2013 Albumin plus terlipressin Albumin plus octreotide 20 20 36 4 Not
stat-
ed
Not
stat-
ed
Not stat-
ed
Not
stated
Not stat-
ed
Not stated 1 High
Tavakkoli
2012
Albumin plus noradrenaline Albumin plus midodrine
plus octreotide
11 12 15 8 Not
stat-
ed
Not
stat-
ed
Not stat-
ed
Not
stated
Not stat-
ed
2011-2012 3 High
Table 2.   Potential e:ect modifiers  (Continued)
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Stine 2018 Albumin plus midodrine
plus octreotide
Albumin plus midodrine
plus octreotide plus pen-
toxifylline
6 6 12 0 Not
stat-
ed
Not
stat-
ed
Not stat-
ed
Not
stated
Not stat-
ed
2014-2016 6 High
Chelarescu
2003
Captopril plus octreotide Octreotide 13 12 Not
stat-
ed
Not
stat-
ed
Not
stat-
ed
Not
stat-
ed
Not stat-
ed
Not
stated
Not stat-
ed
Not stated 0.2 High
Koch 2016 Goal-directed therapy No goal-directed therapy 16 9 Not
stat-
ed
Not
stat-
ed
22 2 1 0 Not stat-
ed
Not stated 1 High
Mitzner
2000
Haemofiltration MARS 5 8 13 0 7 4 1 1 Yes Not stated 1 High
Daskalopou-
los 1985
Peritoneovenous shunt Medical (no further de-
tails)
11 15 Not
stat-
ed
Not
stat-
ed
28 Not
stat-
ed
Not stat-
ed
Not
stated
Not stat-
ed
1978-1983 0.5 High
Table 2.   Potential e:ect modifiers  (Continued)
*Number of participants not stated, but both participants with type I and type II HRS included in the study
MARS: molecular adsorbent recirculating system
 
 
Study name Intervention 1 Intervention 2 Se-
quence
genera-
tion
Allo-
cation
conceal-
ment
Blind-
ing of
patients
and
health-
care
providers
Blinding
of out-
come
asses-
sors
Miss-
ing out-
come
bias
Selec-
tive out-
come
report-
ing
Overall
risk of
bias
Alessandria 2007 Albumin plus terlipressin Albumin plus noradrenaline unclear unclear high high low unclear High
Arora 2018 Albumin plus terlipressin Albumin plus noradrenaline unclear low high high low low High
Badawy 2013 Albumin plus terlipressin Albumin plus noradrenaline unclear unclear high high high unclear High
Ghosh 2013 Albumin plus terlipressin Albumin plus noradrenaline low unclear high high unclear low High
Goyal 2008 Albumin plus terlipressin Albumin plus noradrenaline unclear unclear high high unclear unclear High
Table 3.   Risk of bias (arranged by intervention) 
C
o
ch
ra
n
e
L
ib
ra
ry
T
ru
ste
d
 e
v
id
e
n
ce
.
In
fo
rm
e
d
 d
e
cisio
n
s.
B
e
tte
r h
e
a
lth
.
  
C
o
ch
ra
n
e D
a
ta
b
a
se o
f S
ystem
a
tic R
e
vie
w
s
T
re
a
tm
e
n
t fo
r h
e
p
a
to
re
n
a
l sy
n
d
ro
m
e
 in
 p
e
o
p
le
 w
ith
 d
e
co
m
p
e
n
sa
te
d
 liv
e
r cirrh
o
sis: a
 n
e
tw
o
rk
 m
e
ta
-a
n
a
ly
sis (R
e
v
ie
w
)
C
o
p
yrig
h
t ©
 2019 T
h
e C
o
ch
ra
n
e C
o
lla
b
o
ra
tio
n
. P
u
b
lish
ed
 b
y Jo
h
n
 W
ile
y &
 S
o
n
s, Ltd
.
9
0
Goyal 2016 Albumin plus terlipressin Albumin plus noradrenaline low unclear high high low low High
Indrabi 2013 Albumin plus terlipressin Albumin plus noradrenaline unclear unclear unclear unclear low unclear High
Saif 2018 Albumin plus terlipressin Albumin plus noradrenaline low unclear unclear unclear low unclear High
Sharma 2008 Albumin plus terlipressin Albumin plus noradrenaline low unclear high high low unclear High
Singh 2012 Albumin plus terlipressin Albumin plus noradrenaline low unclear high high unclear unclear High
Boyer 2016 Albumin plus terlipressin Albumin low low low low low low High
Martin-Llahi 2008 Albumin plus terlipressin Albumin low low high high low low High
Neri 2008 Albumin plus terlipressin Albumin low low unclear unclear low unclear High
Sanyal 2008 Albumin plus terlipressin Albumin low low low low low low Low
Solanki 2003 Albumin plus terlipressin Albumin low unclear high unclear low unclear High
Yang 2001 Albumin plus terlipressin Albumin unclear unclear unclear unclear unclear unclear High
Zafar 2012 Albumin plus terlipressin Albumin unclear unclear unclear unclear unclear unclear High
Cavallin 2015 Albumin plus terlipressin Albumin plus midodrine plus oc-
treotide
low low unclear unclear high low High
Copaci 2013 Albumin plus terlipressin Albumin plus octreotide unclear unclear unclear unclear unclear unclear High
Tavakkoli 2012 Albumin plus noradrenaline Albumin plus midodrine plus oc-
treotide
unclear unclear unclear unclear low unclear High
Stine 2018 Albumin plus midodrine
plus octreotide
Albumin plus midodrine plus oc-
treotide plus pentoxifylline
unclear unclear low low low unclear High
Chelarescu 2003 Captopril plus octreotide Octreotide unclear unclear unclear unclear unclear unclear High
Koch 2016 Goal directed therapy No goal-directed therapy unclear unclear unclear unclear unclear unclear High
Mitzner 2000 Haemofiltration MARS low low unclear unclear unclear unclear High
Table 3.   Risk of bias (arranged by intervention)  (Continued)
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Daskalopoulos
1985
Peritoneovenous shunt Medical (no further details) unclear unclear unclear unclear high unclear High
Table 3.   Risk of bias (arranged by intervention)  (Continued)
MARS: molecular adsorbent recirculating system
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All-cause mortality Fixed-effect model Random-effects model Inconsistency model
Dbar 176.9 153.6 153.7
DIC 199.9 184.8 185.7
pD 22.93 31.22 31.95
Serious adverse events (propor-
tion)
Fixed-effect model Random-effects model Inconsistency model
Dbar 31.03 31.57 31.6
DIC 36.04 37.3 37.35
pD 5.01 5.72 5.76
Serious adverse events (number
per participant)
Fixed-effect model Random-effects model Inconsistency model
Dbar 21.16 21.17 21.15
DIC 25.12 25.13 25.09
pD 3.95 3.96 3.94
Any adverse events (proportion) Fixed-effect model Random-effects model Inconsistency model
Dbar 33.95 34.58 34.57
DIC 40.9 42.16 42.14
pD 6.96 7.58 7.57
Any adverse events (number per
participant)
Fixed-effect model Random-effects model Inconsistency model
Dbar 46.84 46.83 47.86
DIC 53.71 53.67 55.86
pD 6.87 6.84 8.01
Liver transplantation Fixed-effect model Random-effects model Inconsistency model
Dbar 29.12 29.77 29.79
DIC 34.12 35.48 35.51
pD 4.99 5.71 5.72
Recovery from hepatorenal syn-
drome
Fixed-effect model Random-effects model Inconsistency model
Dbar 169.2 161.1 159
Table 4.   Model fit 
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DIC 191.9 189.9 187.3
pD 22.64 28.85 28.3
Table 4.   Model fit  (Continued)
Abbreviations
DBar = posterior mean of deviance
DIC = deviance information criteria
pD = effective number of parameters or leverage
 
 
All-cause mortality Albumin + Terli-
pressin
Albumin + Noradren-
aline
Albumin Albumin
+ Mido-
drine
+ Oc-
treotide
Albumin
+ Mido-
drine
+ Oc-
treotide +
Pentoxy-
fylline
Albu-
min + Oc-
treotide
Albumin + Terlipressin - 1.36 [0.92,1.91] 1.19
[0.46,4.61]
1.62
[0.68,3.82]
- 1.45
[0.49,4.49]
Albumin + Noradrenaline 1.33 [0.87,2.00] - - 0.88
[0.26,2.94]
- -
Albumin 1.06 [0.69,1.80] 0.80 [0.44,1.60] - - - -
Albumin + Midodrine +
Octreotide
1.42 [0.52,3.79] 1.07 [0.39,2.89] 1.33
[0.42,3.91]
- 0.36
[0.06,1.66]
-
Albumin + Midodrine +
Octreotide + Pentoxy-
fylline
0.50 [0.06,4.07] 0.38 [0.04,3.07] 0.47
[0.05,3.98]
0.36
[0.05,2.21]
- -
Albumin + Octreotide 1.46 [0.35,6.49] 1.10 [0.25,5.26] 1.37
[0.29,6.44]
1.03
[0.18,6.32]
2.92
[0.23,42.06]
-
Serious adverse events
(proportion)
Albumin + Terli-
pressin
Albumin + Noradren-
aline
Albumin
Albumin + Terlipressin - 0.81 [0.21,2.93] 0.80
[0.50,1.26]
Albumin + Noradrenaline 0.82 [0.21,2.98] - -
Albumin 0.80 [0.50,1.26] 0.98 [0.25,3.99] -
-
Serious adverse events
(number per partici-
pant)
Albumin + Terli-
pressin
Albumin + Noradren-
aline
Albumin
Albumin + Terlipressin - 0.82 [0.23,2.82] 0.92
[0.51,1.63]
Albumin + Noradrenaline 0.83 [0.23,2.83] - -
-
Table 5.   E:ect estimates 
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Albumin 0.91 [0.51,1.65] 1.11 [0.28,4.53] -
Any adverse events
(proportion)
Albumin + Terli-
pressin
Albumin + Noradren-
aline
Albumin Albumin
+ Mido-
drine
+ Oc-
treotide
Albumin + Terlipressin - 0.16 [0.01,1.46] 0.58
[0.25,1.28]
1.14
[0.30,4.30]
Albumin + Noradrenaline 0.16 [0.01,1.44] - - -
Albumin 0.58 [0.25,1.25] 3.65 [0.36,113.18] - -
Albumin + Midodrine +
Octreotide
1.14 [0.30,4.27] 7.40 [0.53,262.96] 1.95
[0.42,9.21]
-
-
Any adverse events
(number per partici-
pant)
Albumin + Terli-
pressin
Albumin + Noradren-
aline
Albumin
Albumin + Terlipressin - 0.51 [0.28,0.87] 0.79
[0.52,1.21]
Albumin + Noradrenaline 0.50 [0.28,0.88] - -
Albumin 0.80 [0.52,1.22] 1.59 [0.78,3.20] -
-
Liver transplantation Albumin + Terli-
pressin
Albumin + Noradren-
aline
Albumin
Albumin + Terlipressin - 1.09 [0.36,3.23] 1.01
[0.68,1.52]
Albumin + Noradrenaline 1.09 [0.36,3.31] - -
Albumin 1.01 [0.68,1.52] 0.93 [0.28,3.06] -
-
Recovery from hepa-
torenal syndrome
Albumin + Terli-
pressin
Albumin + Noradren-
aline
Albumin Albumin
+ Mido-
drine
+ Oc-
treotide
Albumin
+ Mido-
drine
+ Oc-
treotide +
Pentoxy-
fylline
Albu-
min + Oc-
treotide
Albumin + Terlipressin - 0.90 [0.64,1.29] 0.27
[0.05,1.17]
0.04
[0.00,0.25]
- 0.26
[0.07,0.80]
Albumin + Noradrenaline 0.85 [0.58,1.28] - - 0.87
[0.26,2.91]
- -
Albumin 0.28 [0.14,0.53] 0.33 [0.14,0.69] - - - -
Albumin + Midodrine +
Octreotide
0.26 [0.08,0.79] 0.30 [0.09,0.92] 0.92
[0.24,3.53]
- 1.00
[0.02,38.67]
-
Table 5.   E:ect estimates  (Continued)
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Albumin + Midodrine +
Octreotide + Pentoxy-
fylline
0.25 [0.00,12.85] 0.30 [0.01,14.78] 0.91
[0.02,48.76]
1.06
[0.02,46.34]
- -
Albumin + Octreotide 0.26 [0.05,1.12] 0.31 [0.06,1.40] 0.95
[0.16,4.78]
1.03
[0.14,6.98]
1.03
[0.01,65.17]
-
Table 5.   E:ect estimates  (Continued)
The table provides the effect estimates (proportion of people with serious adverse events and any adverse events; hazard ratio for all-cause
mortality, and recovery from hepatorenal syndrome; and rate ratio for number of serious adverse events and any adverse events, other
than decompensation) of each pairwise comparison for the different outcomes. The top half of the table indicates the effect estimates
from the direct comparisons. The bottom half of the table indicates the effect estimates from the network meta-analysis. For network
meta-analysis, to identify the effect estimate of a comparison, say A versus B, look at the cell that occupies the row corresponding to
intervention A and the column corresponding to intervention B for the direct effect estimate. If that cell is empty (indicated by a '-'), look at
the row corresponding to intervention B and the column corresponding to intervention A. Take the inverse of this number (i.e. 1/number)
to arrive at the treatment effect of A versus B. For direct comparisons, this is exactly the opposite; look at the cell that occupies the column
corresponding to intervention A and the row corresponding to intervention B for the direct effect estimate. If that cell is empty, look at
the column corresponding to intervention B and the row corresponding to intervention A. Take the inverse of this number to arrive at the
treatment effect of A versus B. If the cell corresponding to B versus A is also missing in direct comparisons, this means that there was no
direct comparison.
Except for the differences shown in italics for number of adverse events (lower with albumin + noradrenaline versus albumin + terlipressin)
(direct comparison and network meta-analysis) and for recovery from hepatorenal syndrome (lower with albumin + midodrine + octreotide
versus albumin + terlipressin in direct comparison and network meta-analysis; lower with albumin + octreotide versus albumin + terli-
pressin in direct comparison only; and lower with albumin alone versus albumin + terlipressin and albumin + noradrenaline and albumin
+ midodrine + octreotide versus albumin + noradrenaline in network meta-analysis only), there was no evidence of a difference in any of
the other comparisons in direct comparisons or network meta-analysis.
 
 
A P P E N D I C E S
Appendix 1. Glossary of terms
Analogue - something which is different but very similar to something else. In the context of drugs, this is usually a drug which acts in the
same way as a molecule produced by the body.
Ascites - buildup of protein-containing fluid in the abdomen, most commonly as a result of liver disease
Coagulopathy - disorder of blood clotting which causes a tendency towards prolonged or excessive bleeding
Decompensated cirrhosis - the liver can accommodate for some loss of function which occurs at the beginning of the cirrhosis. However,
eventually the scarring means the liver cannot perform its essential functions and the patient develops symptoms, this is then termed
decompensated cirrhosis
Fibrous septa - sheets of tissue made of collagen which divide two areas
Hepatic - of, or relating to, the liver
Hepatic encephalopathy - a lowered level of consciousness or other neurological symptoms as a results of liver failure. It is caused by
build-up of ammonia in the blood, something which is normally prevented by the liver
Intravascular - contained by blood vessels
Nephrotoxic - damaging to the kidneys
Oncotic - a form of pressure exerted on liquid by proteins
Portal - a venous system which occurs when a capillary bed pools into another capillary bed through veins without going through the
heart; most notably in humans, this occurs in the liver creating the hepatic portal system
Parenchymal nodules - a small mass of tissue made up of the functional tissue of an organ
Transjugular - through the internal jugular vein, which is a large neck vein
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Variceal bleeding - loss of blood from dilated veins just below the gut lining, most commonly occurring in the lower portion of the oesoph-
agus or upper stomach
Vasocontrictor - a substance that causes the narrowing of blood vessels
Appendix 2. Search strategies
 
Database Time span Search strategy
Central Register of Con-
trolled Trials (CENTRAL) in
the Cochrane Library
Issue 12, 2018 #1 MeSH descriptor: [Hepatorenal Syndrome] explode all trees
#2 hepatorenal syndrom*
#3 #1 or #2
MEDLINE Ovid January 1947 to
December 2018
1. exp Hepatorenal Syndrome/
2. hepatorenal syndrom*.ti,ab.
3. 1 or 2
4. randomized controlled trial.pt.
5. controlled clinical trial.pt.
6. randomized.ab.
7. placebo.ab.
8. drug therapy.fs.
9. randomly.ab.
10. trial.ab.
11. groups.ab.
12. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. exp animals/ not humans.sh.
14. 12 not 13
15. 3 and 14
Embase Ovid January 1974 to
December 2018
1. exp hepatorenal syndrome/
2. hepatorenal syndrom*.ti,ab.
3. 1 or 2
4. exp crossover-procedure/ or exp double-blind procedure/ or exp random-
ized controlled trial/ or single-blind procedure/
5. (((((random* or factorial* or crossover* or cross over* or cross-over* or
placebo* or double*) adj blind*) or single*) adj blind*) or assign* or allocat* or
volunteer*).af.
6. 4 or 5
7. 3 and 6
Science Citation Index Ex-
panded (Web of Science)
January 1945 to
December 2018
#1 TS= (hepatorenal syndrom*)
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#2 TS=(random* OR rct* OR crossover OR masked OR blind* OR placebo* OR
meta-analysis OR systematic review* OR meta-analys*)
#3 #1 AND #2
World Health Organization
International Clinical Tri-
als Registry Platform (app-
s.who.int/trialsearch/De-
fault.aspx)
December 2018 Condition: hepatorenal syndrome
ClinicalTrials.gov December 2018 Interventional Studies | Hepatorenal Syndrome | Phase 2, 3, 4
European Medicines Agency
(www.ema.europa.eu/ema/)
and US Food and Drug Ad-
ministration (www.fda.gov)
December 2018 Hepatorenal syndrome
  (Continued)
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8
#Mortality; 1 = Albumin plus terlipressin; 2 = Albumin plus noradrenaline; 3 = Albumin; 4 = Albumin plus midodrine plus octreotide; 5 = Albumin plus midodrine
plus octreotide plus pentoxyfylline; 6 = Albumin plus octreotide
list(nt=6,ns.a=18,ns2=1,ns3=0,ns4=0)                      
t.a[,1] t.a[,2] t.a[,3] t.a[,4] r.a[,1] r.a[,2] r.a[,3] r.a[,4] n.a[,1] n.a[,2] n.a[,3] n.a[,4] na.a[]time.a[] #study
1 2 NA NA 4 3 NA NA 12 10 NA NA 2 1 #Alessandria 2007
1 2 NA NA 12 13 NA NA 26 25 NA NA 2 0.5 #Badawy 2013
1 2 NA NA 8 9 NA NA 23 23 NA NA 2 3 #Ghosh 2013
1 2 NA NA 11 11 NA NA 20 21 NA NA 2 0.5 #Goyal 2016
1 2 NA NA 28 29 NA NA 30 30 NA NA 2 3 #Indrabi 2013
1 2 NA NA 9 9 NA NA 20 20 NA NA 2 0.5 #Sharma 2008
1 2 NA NA 16 15 NA NA 23 23 NA NA 2 1 #Singh 2012
1 2 NA NA 31 48 NA NA 60 60 NA NA 2 1 #Arora 2018
1 2 NA NA 24 29 NA NA 30 30 NA NA 2 3 #Saif 2018
1 3 NA NA 40 43 NA NA 97 99 NA NA 2 3 #Boyer 2016
1 3 NA NA 17 19 NA NA 23 23 NA NA 2 3 #Martin-Llahi 2008
1 3 NA NA 32 35 NA NA 56 56 NA NA 2 6 #Sanyal 2008
1 3 NA NA 7 12 NA NA 12 12 NA NA 2 0.5 #Solanki 2003
1 3 NA NA 19 20 NA NA 25 25 NA NA 2 3 #Zafar 2012
1 4 NA NA 11 12 NA NA 27 21 NA NA 2 3 #Cavallin 2015
1 6 NA NA 6 8 NA NA 20 20 NA NA 2 1 #Copaci 2013
2 4 NA NA 6 6 NA NA 11 12 NA NA 2 3 #Tavakkoli 2012
4 5 NA NA 5 3 NA NA 6 6 NA NA 2 6 #Stine 2018
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END                            
t[,1] t[,2] t[,3] t[,4] y[,2] y[,3] y[,4] se[,2] se[,3] se[,4] na[] V[] #study   
1 3 NA NA -0.83 NA NA 0.18 NA NA 2 NA #Neri 2008  
END                            
#Mortality; 1 = Captopril plus octreotide; 2 = Octreotide
list(nt=2,ns=1)                          
t[,1] t[,2] t[,3] t[,4] r[,1] r[,2] r[,3] r[,4] n[,1] n[,2] n[,3] n[,4] na[] time[] #study
1 2 NA NA 1 2 NA NA 13 12 NA NA 2 0.1 #Chelarescu 2003
END                            
#Mortality; 1 = Haemofiltration; 2 = MARS
list(nt=2,ns=1)                          
t[,1] t[,2] t[,3] t[,4] r[,1] r[,2] r[,3] r[,4] n[,1] n[,2] n[,3] n[,4] na[] time[] #study
1 2 NA NA 5 6 NA NA 5 8 NA NA 2 1 #Mitzner 2000
END                            
#Mortality; 1 = Medical; 2 = Surgical
list(nt=2,ns=1)                          
t[,1] t[,2] t[,3] t[,4] r[,1] r[,2] r[,3] r[,4] n[,1] n[,2] n[,3] n[,4] na[] time[] #study
1 2 NA NA 13 8 NA NA 15 11 NA NA 2 0.5 #Daskalopoulos 1985
END                            
#SAE_Num; 1 = Albumin plus terlipressin; 2 = Albumin plus noradrenaline; 3 = Albumin
list(nt=3,ns=2)                          
  (Continued)
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0
0
t[,1] t[,2] t[,3] t[,4] r[,1] r[,2] r[,3] r[,4] E[,1] E[,2] E[,3] E[,4] na[] time[] #study
1 2 NA NA 6 5 NA NA 60 60 NA NA 2 1 #Arora 2018
1 3 NA NA 24 22 NA NA 23 23 NA NA 2 3 #Martin-Llahi 2008
END                            
#SAE_Prop; 1 = Albumin plus terlipressin; 2 = Albumin plus noradrenaline; 3 = Albumin
list(nt=3,ns=3)                          
t[,1] t[,2] t[,3] t[,4] r[,1] r[,2] r[,3] r[,4] n[,1] n[,2] n[,3] n[,4] na[] time[] #study
1 2 NA NA 6 5 NA NA 60 60 NA NA 2 1 #Arora 2018
1 3 NA NA 59 53 NA NA 97 99 NA NA 2 3 #Boyer 2016
1 3 NA NA 37 36 NA NA 56 56 NA NA 2 6 #Sanyal 2008
END                            
#AE_Num; 1 = Albumin plus terlipressin; 2 = Albumin plus noradrenaline; 3 = Albumin
list(nt=3,ns=5)                          
t[,1] t[,2] t[,3] t[,4] r[,1] r[,2] r[,3] r[,4] E[,1] E[,2] E[,3] E[,4] na[] time[] #study
1 2 NA NA 5 3 NA NA 20 21 NA NA 2 0.5 #Goyal 2016
1 2 NA NA 5 3 NA NA 20 20 NA NA 2 0.5 #Sharma 2008
1 2 NA NA 6 2 NA NA 23 23 NA NA 2 1 #Singh 2012
1 2 NA NA 19 10 NA NA 60 60 NA NA 2 1 #Arora 2018
1 3 NA NA 50 40 NA NA 23 23 NA NA 2 3 #Martin-Llahi 2008
END                            
#AE_Prop; 1 = Albumin plus terlipressin; 2 = Albumin plus noradrenaline; 3 = Albumin; 4 = Albumin plus midodrine plus octreotide
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list(nt=4,ns=4)                          
t[,1] t[,2] t[,3] t[,4] r[,1] r[,2] r[,3] r[,4] n[,1] n[,2] n[,3] n[,4] na[] time[] #study
1 2 NA NA 4 1 NA NA 23 23 NA NA 2 3 #Ghosh 2013
1 3 NA NA 90 88 NA NA 97 99 NA NA 2 3 #Boyer 2016
1 3 NA NA 52 49 NA NA 56 56 NA NA 2 6 #Sanyal 2008
1 4 NA NA 7 6 NA NA 27 21 NA NA 2 3 #Cavallin 2015
END                            
#LiverTransplant; 1 = Albumin plus terlipressin; 2 = Albumin plus noradrenaline; 3 = Albumin
list(nt=3,ns=3)                          
t[,1] t[,2] t[,3] t[,4] r[,1] r[,2] r[,3] r[,4] n[,1] n[,2] n[,3] n[,4] na[] time[] #study
1 2 NA NA 8 7 NA NA 12 10 NA NA 2 1 #Alessandria 2007
1 3 NA NA 30 32 NA NA 97 99 NA NA 2 3 #Boyer 2016
1 3 NA NA 18 17 NA NA 56 56 NA NA 2 6 #Sanyal 2008
END                            
#LiverTransplant: 1 = Albumin plus midodrine plus octreotide; 2=Albumin plus midodrine plus octreotide plus pentoxyfylline
list(nt=2,ns=1)                          
t[,1] t[,2] t[,3] t[,4] r[,1] r[,2] r[,3] r[,4] n[,1] n[,2] n[,3] n[,4] na[] time[] #study
1 2 NA NA 1 1 NA NA 6 6 NA NA 2 6 #Stine 2018
END                            
#RecoveryFromHRS; 1 = Albumin plus terlipressin; 2 = Albumin plus noradrenaline; 3 = Albumin; 4 = Albumin plus midodrine plus octreotide; 5 = Albumin plus mi-
dodrine plus octreotide plus pentoxyfylline; 6 = Albumin plus octreotide
list(nt=6,ns=18)                          
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2
t[,1] t[,2] t[,3] t[,4] r[,1] r[,2] r[,3] r[,4] n[,1] n[,2] n[,3] n[,4] na[] time[] #study
1 2 NA NA 6 6 NA NA 12 10 NA NA 2 1 #Alessandria 2007
1 2 NA NA 12 10 NA NA 26 25 NA NA 2 0.5 #Badawy 2013
1 2 NA NA 15 14 NA NA 23 23 NA NA 2 3 #Ghosh 2013
1 2 NA NA 7 9 NA NA 16 16 NA NA 2 0.5 #Goyal 2008
1 2 NA NA 9 10 NA NA 20 21 NA NA 2 0.5 #Goyal 2016
1 2 NA NA 16 15 NA NA 30 30 NA NA 2 3 #Indrabi 2013
1 2 NA NA 8 10 NA NA 20 20 NA NA 2 0.5 #Sharma 2008
1 2 NA NA 9 10 NA NA 23 23 NA NA 2 1 #Singh 2012
1 2 NA NA 24 10 NA NA 60 60 NA NA 2 1 #Arora 2018
1 2 NA NA 16 15 NA NA 30 30 NA NA 2 3 #Saif 2018
1 3 NA NA 18 12 NA NA 97 99 NA NA 2 3 #Boyer 2016
1 3 NA NA 10 2 NA NA 23 23 NA NA 2 3 #Martin-Llahi 2008
1 3 NA NA 21 5 NA NA 26 26 NA NA 2 3 #Neri 2008
1 3 NA NA 19 7 NA NA 56 56 NA NA 2 6 #Sanyal 2008
1 4 NA NA 15 1 NA NA 27 21 NA NA 2 3 #Cavallin 2015
1 6 NA NA 11 4 NA NA 20 20 NA NA 2 1 #Copaci 2013
2 4 NA NA 6 6 NA NA 11 12 NA NA 2 3 #Tavakkoli 2012
4 5 NA NA 1 1 NA NA 6 6 NA NA 2 6 #Stine 2018
END                            
#OtherDecompensation: 1 = Albumin plus terlipressin; 2 = Albumin
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list(nt=2,ns=1)                          
t[,1] t[,2] t[,3] t[,4] r[,1] r[,2] r[,3] r[,4] E[,1] E[,2] E[,3] E[,4] na[] time[] #study
1 2 NA NA 20 22 NA NA 23 23 NA NA 2 3 #Martin-Llahi 2008
END                            
#Costs; 1 = Albumin plus terlipressin; 2 = Albumin plus noradrenaline
list(nt=2,ns=5)                          
t[,1] t[,2] t[,3] t[,4] y[,1] y[,2] y[,3] y[,4] se[,1] se[,2] se[,3] se[,4] na[] time[] #study
1 2 NA NA 1895.58 132.05 NA NA 14.2 12.1 NA NA 2 1 #Alessandria 2007
1 2 NA NA 340.59 83.03 NA NA 19.6 9.5 NA NA 2 0.5 #Badawy 2013
1 2 NA NA 2500 750 NA NA 436 436 NA NA 2 0.5 #Sharma 2008
1 2 NA NA 1290.36 363.95 NA NA 325.6 325.6 NA NA 2 1 #Singh 2012
1 2 NA NA 1434.23 268.92 NA NA 411.7 411.7 NA NA 2 3 #Saif 2018
END                            
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1. We did not perform Trial Sequential Analysis (TSA), as the risk of false positive results with Bayesian meta-analysis is probably less or
at least equivalent to TSA.
2. We used the latest guidance from the GRADE Working group (Yepes-Nunez 2019) rather than the previous guidance (Puhan 2014) for
presenting the 'Summary of Findings' table.
3. The trials did not report the proportion of people with other episodes of decompensation, but reported the number of episodes of
decompensation. Therefore, we treated this as a count outcome and used the Poisson likelihood to calculate the rate ratio.
4. In the absence of a protocol published prior to the start of the study, we have classified the risk of bias as low for selective reporting
bias only when mortality, adverse events, and hepatorenal syndrome were reported, as we anticipated these outcomes to be routinely
measured in clinical trials of this nature.
5. We used 30,000 iterations as a minimum for burn-in.
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